BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041-1048. [PMID: 13260656 DOI: 10.1136/bmj.2.4947.1041] [Cited by in Crossref: 1735] [Cited by in F6Publishing: 1669] [Article Influence: 91.3] [Reference Citation Analysis]
Number Citing Articles
1 Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Kakkadasam Ramaswamy P, Kumar S, Kedia S, McGregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis SPL, Satsangi J. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 2022:gutjnl-2022-327533. [PMID: 36171080 DOI: 10.1136/gutjnl-2022-327533] [Reference Citation Analysis]
2 Caron B, Jairath V, D'Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L. Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European Gastroenterol J 2022. [PMID: 36029157 DOI: 10.1002/ueg2.12283] [Reference Citation Analysis]
3 Huang C, Huang Z, Ding L, Fu Y, Fan J, Mei Q, Lou L, Wang J, Yin N, Lu Y, Guo S, Zeng Y. Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis. J Transl Med 2022;20:354. [PMID: 35962454 DOI: 10.1186/s12967-022-03569-3] [Reference Citation Analysis]
4 Song Z, Zhang M, Ren Y, Iang B. [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis]. Nan Fang Yi Ke Da Xue Xue Bao 2022;42:997-1005. [PMID: 35869761 DOI: 10.12122/j.issn.1673-4254.2022.07.05] [Reference Citation Analysis]
5 Eiro N, Barreiro-Alonso E, Fraile M, González LO, Altadill A, Vizoso FJ. Expression of MMP-2, MMP-7, MMP-9, and TIMP-1 by Inflamed Mucosa in the Initial Diagnosis of Ulcerative Colitis as a Response Marker for Conventional Medical Treatment. Pathobiology 2022;:1-13. [PMID: 35797965 DOI: 10.1159/000524978] [Reference Citation Analysis]
6 Renaud M, Ayav A, Caron B, Peyrin-biroulet L, Germain A. Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis? JCM 2022;11:3857. [DOI: 10.3390/jcm11133857] [Reference Citation Analysis]
7 Kotze PG, Heuthorst L, Lightner AL, Damião AOMC, Bemelman WA. New insights on the surgical management of ulcerative colitis in the 21st century. The Lancet Gastroenterology & Hepatology 2022;7:679-88. [DOI: 10.1016/s2468-1253(22)00001-2] [Reference Citation Analysis]
8 Kim KO. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. Clin Endosc 2022;55:480-8. [PMID: 35898147 DOI: 10.5946/ce.2022.108] [Reference Citation Analysis]
9 Macleod A, Kavalukas SL, Scheurlen KM, Galandiuk S. State-of-the-art surgery for Crohn's disease: Part II-colonic Crohn's disease and associated neoplasms. Langenbecks Arch Surg 2022. [PMID: 35729401 DOI: 10.1007/s00423-022-02572-y] [Reference Citation Analysis]
10 Xu F, Hu J, Yang Q, Ji Y, Cheng C, Zhu L, Shen H. Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02357-z] [Reference Citation Analysis]
11 Okabayashi S, Yamazaki H, Tominaga K, Miura M, Sagami S, Matsuoka K, Yamaguchi Y, Noake T, Ozeki K, Miyazaki R, Kamano T, Fukuda T, Yoshioka K, Ando K, Fukuzawa M, Andoh A, Yamamoto Y, Hibi T, Kobayashi T; IBD Terakoya Group. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther 2022;55:1569-80. [PMID: 35274323 DOI: 10.1111/apt.16865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chiarello MM, Pepe G, Fico V, Bianchi V, Tropeano G, Altieri G, Brisinda G. Therapeutic strategies in Crohn’s disease in an emergency surgical setting. World J Gastroenterol 2022; 28(18): 1902-1921 [DOI: 10.3748/wjg.v28.i18.1902] [Reference Citation Analysis]
13 Sahu P, Jain S, Kedia S, Vuyyuru SK, Sahni P, Sharma R, Panwar R, Das P, Gupta V, Makharia G, Travis S, Ahuja V. Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. Indian J Gastroenterol 2022. [PMID: 35474175 DOI: 10.1007/s12664-021-01217-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang M, Lv H, Yang H, Zhang H, Bai X, Qian J. Elderly Patients with Moderate-To-Severe Ulcerative Colitis Are More Likely to Have Treatment Failure and Adverse Outcome. Gerontology 2022;:1-11. [PMID: 35385844 DOI: 10.1159/000522569] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Calabrese E, Monteleone G. Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab. JCM 2022;11:1679. [DOI: 10.3390/jcm11061679] [Reference Citation Analysis]
16 Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Reference Citation Analysis]
17 Xu HM, Zhao HL, Guo GJ, Xu J, Zhou YL, Huang HL, Nie YQ. Characterization of short-chain fatty acids in patients with ulcerative colitis: a meta-analysis. BMC Gastroenterol 2022;22:117. [PMID: 35272614 DOI: 10.1186/s12876-022-02191-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Mishra S, Ram S, Prasad KK, Sharma AK, Dutta U, Sharma V. SERUM PROCALCITONIN AS A PROGNOSTIC MARKER IN ACUTE SEVERE ULCERATIVE COLITIS: A PROSPECTIVE STUDY. Arq Gastroenterol 2022;59:75-9. [DOI: 10.1590/s0004-2803.202200001-14] [Reference Citation Analysis]
19 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sasidharan S, Sasson AN, Shannon KM, Ananthakrishnan AN. Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. Inflamm Bowel Dis 2022:izac011. [PMID: 35134899 DOI: 10.1093/ibd/izac011] [Reference Citation Analysis]
21 Rieker L, Hofer J, Petzold G, Ellenrieder V, Amanzada A. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report. BMC Gastroenterol 2022;22:22. [PMID: 35033015 DOI: 10.1186/s12876-022-02094-3] [Reference Citation Analysis]
22 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
23 Vitello D, Mcgee MF. Treatment of severe and fulminant colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100864] [Reference Citation Analysis]
24 Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang XF, Li P, Ding XL, Chen H, Wang SJ, Jin SB, Guo J, Tian ZB. Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis. Gastroenterol Rep (Oxf) 2021;9:533-42. [PMID: 34925850 DOI: 10.1093/gastro/goab026] [Reference Citation Analysis]
26 Geldof J, LeBlanc JF, Lucaciu L, Segal J, Lees CW, Hart A. Are we addressing the top 10 research priorities in IBD? Frontline Gastroenterol 2021;12:564-9. [PMID: 34917313 DOI: 10.1136/flgastro-2020-101579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang M, Bai X, Zhang H, You Y, Lv H, Li Y, Tan B, Li J, Xu H, Zheng W, Yang H, Qian J. The role of cytomegalovirus colitis on short- and long-term outcomes for patients with ulcerative colitis. Scand J Gastroenterol 2021;:1-8. [PMID: 34894997 DOI: 10.1080/00365521.2021.2006298] [Reference Citation Analysis]
28 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Markovic S, Jankovic M, Kalaba A, Zogovic B, Sreckovic SS. Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series. Cureus 2021;13:e19019. [PMID: 34824934 DOI: 10.7759/cureus.19019] [Reference Citation Analysis]
30 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Biancone L, Calabrese E, Monteleone G. Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. J Clin Med 2021;10:5413. [PMID: 34830694 DOI: 10.3390/jcm10225413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yamamoto-Furusho JK, Parra-Holguín NN. Real-world experience with MMX mesalazine use in Mexican patients with ulcerative colitis at two tertiary care centers. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00060-8. [PMID: 34794923 DOI: 10.1016/j.rgmxen.2021.06.002] [Reference Citation Analysis]
32 Horio Y, Uchino M, Hori K, Kusunoki K, Minagawa T, Kuwahara R, Kataoka K, Beppu N, Ikeda M, Ikeuchi H. Clinical Features and Therapeutic Outcomes of Post-colectomy Enteritis with Ulcerative Colitis. J Anus Rectum Colon 2021;5:405-13. [PMID: 34746505 DOI: 10.23922/jarc.2021-031] [Reference Citation Analysis]
33 Hishinuma K, Moroi R, Okamoto D, Shimoyama Y, Kuroha M, Shiga H, Kakuta Y, Kinouchi Y, Masamune A. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci. Inflamm Intest Dis 2021;6:154-64. [PMID: 34722645 DOI: 10.1159/000518371] [Reference Citation Analysis]
34 Ma L, Pang X, Ji G, Ma X, Li J, Chang Y, Ma C. Application of the neutrophil to lymphocyte ratio in the diagnosis and activity determination of ulcerative colitis: A meta-analysis and systematic review. Medicine (Baltimore) 2021;100:e27551. [PMID: 34678891 DOI: 10.1097/MD.0000000000027551] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Prentice R, Al-Ani A, Cherry T, Dixon-Douglas J, Eccles-Smith J, Matheson J, Tie J, Thevathasan I, McCormick JJ, Christensen B. Evaluation and management of rectal bleeding in pregnancy. Med J Aust 2021;215:377-82. [PMID: 34601746 DOI: 10.5694/mja2.51267] [Reference Citation Analysis]
36 Mori R, Ogino T, Sekido Y, Hata T, Takahashi H, Miyoshi N, Uemura M, Doki Y, Eguchi H, Mizushima T. Long Distance Between the Superior Mesenteric Artery Root and Bottom of the External Anal Sphincter Is a Risk Factor for Stoma Outlet Obstruction After Total Proctocolectomy and Ileal‐Pouch Anal Anastomosis for Ulcerative Colitis. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12512] [Reference Citation Analysis]
37 Zhang T, Li G, Duan M, Lv T, Feng D, Lu N, Zhou Y, Gu L, Zhu W, Gong J. Perioperative parenteral fish oil supplementation improves postoperative coagulation function and outcomes in patients undergoing colectomy for ulcerative colitis. JPEN J Parenter Enteral Nutr 2021. [PMID: 34609004 DOI: 10.1002/jpen.2269] [Reference Citation Analysis]
38 Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR, Probert C, Fraser A, Cheshire A, Lewis A, Sugrue K, Laird S, Scott G. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Br J Hosp Med (Lond) 2021;82:1-11. [PMID: 34726945 DOI: 10.12968/hmed.2021.0399] [Reference Citation Analysis]
39 Gomollón F. Inflammatory bowel disease and corticosteroids: the first RCT. Nat Rev Gastroenterol Hepatol 2021;18:833. [PMID: 34545242 DOI: 10.1038/s41575-021-00524-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Soriano CR, Powell CR, Chiorean MV, Simianu VV. Role of hospitalization for inflammatory bowel disease in the post-biologic era. World J Clin Cases 2021; 9(26): 7632-7642 [PMID: 34621815 DOI: 10.12998/wjcc.v9.i26.7632] [Reference Citation Analysis]
41 Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol 2021;14:343-51. [PMID: 34511961 DOI: 10.2147/CEG.S237653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Luo D, Zhou M, Sun L, Lin Z, Bian Q, Liu M, Ren S. Resilience as a Mediator of the Association Between Perceived Stigma and Quality of Life Among People With Inflammatory Bowel Disease. Front Psychiatry 2021;12:709295. [PMID: 34421685 DOI: 10.3389/fpsyt.2021.709295] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Kantidakis JD, Moulding R, Knowles SR. Psychological mediators of psychological distress and quality of life in inflammatory bowel disease. J Psychosom Res 2021;149:110596. [PMID: 34418720 DOI: 10.1016/j.jpsychores.2021.110596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Shujun W, Huijie Z, Xia B, Hongjian W. Cerebral venous sinus thrombosis in patients with inflammatory bowel disease: a retrospective study. Sci Rep 2021;11:17004. [PMID: 34417546 DOI: 10.1038/s41598-021-96541-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Günther C, Rothhammer V, Karow M, Neurath M, Winner B. The Gut-Brain Axis in Inflammatory Bowel Disease-Current and Future Perspectives. Int J Mol Sci 2021;22:8870. [PMID: 34445575 DOI: 10.3390/ijms22168870] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
47 Rönnblom A, Ljunggren Ö, Karlbom U. Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort. Scand J Gastroenterol 2021;:1-8. [PMID: 34369245 DOI: 10.1080/00365521.2021.1961309] [Reference Citation Analysis]
48 Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
50 Greuter T, Porchet F, Braga-Neto MB, Rossel JB, Biedermann L, Schreiner P, Scharl M, Schoepfer AM, Safroneeva E, Straumann A, Rogler G, Vavricka SR. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United European Gastroenterol J 2020;8:1196-207. [PMID: 33276710 DOI: 10.1177/2050640620954556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
51 Gryglewski A, Richter P, Szczepanik M. Changes in γδT Cells in Peripheral Blood of Patients with Ulcerative Colitis Exacerbations. Arch Immunol Ther Exp (Warsz) 2021;69:18. [PMID: 34287711 DOI: 10.1007/s00005-021-00620-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis 2021;15:1211-21. [PMID: 33388777 DOI: 10.1093/ecco-jcc/jjaa265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Zhang M, Zhang H, Zhu Q, Bai X, Zhou Q, Ruan G, Li W, Ma L, Xiao M, Yang H, Qian J. Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211030050. [PMID: 34345250 DOI: 10.1177/17562848211030050] [Reference Citation Analysis]
54 Fresán Orellana A, Parra Holguín NN, Yamamoto-Furusho JK. Mental Health Factors Associated With Fatigue in Mexican Patients With Inflammatory Bowel Disease. J Clin Gastroenterol 2021;55:609-14. [PMID: 32675632 DOI: 10.1097/MCG.0000000000001397] [Reference Citation Analysis]
55 Weixler B, Sonnenberg E, Kreis ME. Colitis ulcerosa. coloproctology 2021;43:301-10. [DOI: 10.1007/s00053-021-00547-z] [Reference Citation Analysis]
56 Liu C, Mo LH, Feng BS, Jin QR, Li Y, Lin J, Shu Q, Liu ZG, Liu Z, Sun X, Yang PC. Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. Theranostics 2021;11:7797-812. [PMID: 34335965 DOI: 10.7150/thno.62256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Sicilia B, Arias L, Hontoria G, García N, Badia E, Gomollón F. Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study. Front Med (Lausanne) 2021;8:651685. [PMID: 34249960 DOI: 10.3389/fmed.2021.651685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Yamamoto-Furusho JK, Parra-Holguín NN. Real-world experience with MMX mesalazine use in Mexican patients with ulcerative colitis at two tertiary care centers. Rev Gastroenterol Mex 2021:S0375-0906(21)00058-6. [PMID: 34147309 DOI: 10.1016/j.rgmx.2021.01.010] [Reference Citation Analysis]
59 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bruscoli S, Febo M, Riccardi C, Migliorati G. Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. Front Immunol 2021;12:691480. [DOI: 10.3389/fimmu.2021.691480] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
61 Targownik LE, Bernstein CN, Benchimol EI, Kaplan GG, Singh H, Tennakoon A, Nugent Z, Coward SB, Kuenzig ME, Murthy SK. Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. Am J Gastroenterol 2021;116:1284-93. [PMID: 33767103 DOI: 10.14309/ajg.0000000000001220] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
62 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-biroulet L, Mary J. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology 2021;19:1180-1188.e4. [DOI: 10.1016/j.cgh.2020.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
63 Xiao BH, Ma XD, Lv JJ, Yang T, Liu XJ, An LY, Qi YX, Lu ML, Duan YQ, Sun DL. Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. Int J Clin Pract 2021;:e14365. [PMID: 34008296 DOI: 10.1111/ijcp.14365] [Reference Citation Analysis]
64 Pagnini C, Di Paolo MC, Mariani BM, Urgesi R, Pallotta L, Vitale MA, Villotti G, d’Alba L, De Cesare MA, Di Giulio E, Graziani MG. Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index Are Equally Effective for Endoscopic Activity Evaluation in Ulcerative Colitis Patients in a Real Life Setting. Gastroenterology Insights 2021;12:217-24. [DOI: 10.3390/gastroent12020019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Schauer C, Avery V, Seleq S, Garg P, Wang MTM, Chieng M, Rowan C, Sekra A, Lane M, Walmsley R. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. J Gastroenterol Hepatol 2021. [PMID: 33939853 DOI: 10.1111/jgh.15535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 45.0] [Reference Citation Analysis]
67 Zavala-Solares MR, Salazar-Salas L, Yamamoto-Furusho JK. Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. Gastroenterol Hepatol 2021:S0210-5705(21)00116-3. [PMID: 33872624 DOI: 10.1016/j.gastrohep.2021.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Wang Z, Chen J, Chen Z, Xie L, Wang W. Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora. Saudi J Gastroenterol 2021;27:149-57. [PMID: 33835051 DOI: 10.4103/sjg.SJG_462_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
69 Kanmura S, Morinaga Y, Tanaka A, Komaki Y, Iwaya H, Kumagai K, Mawatari S, Sasaki F, Tanoue S, Hashimoto S, Sameshima Y, Ono Y, Ohi H, Ido A. Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis. Clin Transl Gastroenterol 2021;12:e00331. [PMID: 33825720 DOI: 10.14309/ctg.0000000000000331] [Reference Citation Analysis]
70 Collins SM. Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach. Inflamm Bowel Dis 2020;26:493-501. [PMID: 31970390 DOI: 10.1093/ibd/izaa004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
71 An YK. Common mistakes with steroids. J Gastroenterol Hepatol 2021;36 Suppl 1:30-1. [PMID: 33817842 DOI: 10.1111/jgh.15458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Juliao-baños F, Puentes F, López R, Saffon M, Reyes G, Parra V, Galiano M, Barraza M, Molano J, Álvarez E, Corrales R, Vargas L, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J, Juliao-baños F, Arrubla M, Camargo J, Puentes F, Arango L, López R, García R, Mendoza B, Saffon MA, Roldan LF, Zuleta J, Reyes G, Parra V, Flórez C, Nuñez E, Galiano MT, Barraza M, Sanchez IC, Molano JL, Lizarazo JI, Cuellar I, Álvarez E, Corrales R, Gil F, Vargas LE, Álvarez P, Limas LM, Prieto R, Ballén H, Delgado L, Yance P, Díaz F. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Revista de Gastroenterología de México (English Edition) 2021;86:153-62. [DOI: 10.1016/j.rgmxen.2020.05.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Song EM, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 33783045 DOI: 10.1111/jgh.15508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Sommer K, Wiendl M, Müller TM, Heidbreder K, Voskens C, Neurath MF, Zundler S. Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players. Front Med (Lausanne) 2021;8:643973. [PMID: 33834033 DOI: 10.3389/fmed.2021.643973] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
76 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Horio Y, Uchino M, Kihara T, Bando T, Kuwahara R, Minagawa T, Kusunoki K, Watanabe K, Hirota S, Ikeuchi H. Potential problems of partial resection for colitis-associated cancer in a patient with ulcerative colitis: case report. J Surg Case Rep 2021;2021:rjab086. [PMID: 33777355 DOI: 10.1093/jscr/rjab086] [Reference Citation Analysis]
78 Gong SS, Fan YH, Lv B, Zhang MQ, Xu Y, Zhao J. Fatigue in patients with inflammatory bowel disease in Eastern China. World J Gastroenterol 2021; 27(11): 1076-1089 [PMID: 33776374 DOI: 10.3748/wjg.v27.i11.1076] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
79 Tanaka M, Takagi T, Naito Y, Uchiyama K, Hotta Y, Toyokawa Y, Kashiwagi S, Kamada K, Ishikawa T, Yasuda H, Konishi H, Itoh Y. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open 2021;5:377-81. [PMID: 33732885 DOI: 10.1002/jgh3.12506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Navarrete J, González-moret R, Cortés X, Lisón JF, Soria JM, Baños RM, Cebolla A. Dispositional Mindfulness and Inflammatory Bowel Disease: Mindful Awareness Mediates the Relation Between Severity and Quality of Life, Stress, and Fatigue. Mindfulness 2021;12:1524-33. [DOI: 10.1007/s12671-021-01620-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Juliao-Baños F, Kock J, Arrubla M, Calixto O, Camargo J, Cruz L, Hurtado J, Clavijo A, Donado J, Schwartz S, Abreu MT, Damas OM. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients. Medicine (Baltimore) 2021;100:e24729. [PMID: 33607817 DOI: 10.1097/MD.0000000000024729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Gutierrez Becker B, Arcadu F, Thalhammer A, Gamez Serna C, Feehan O, Drawnel F, Oh YS, Prunotto M. Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. Ther Adv Gastrointest Endosc. 2021;14:2631774521990623. [PMID: 33718871 DOI: 10.1177/2631774521990623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
84 Tanaka M, Nakanishi M, Miyazaki H, Morita R, Eguchi H, Takeda Y, Katayama M, Tanaka M, Bamba M, Shigematsu T. Granulocyte and Monocyte Adsorptive Apheresis for Ulcerative Colitis in a Patient with Low Bone Mineral Density Due to Fanconi-Bickel Syndrome. Intern Med 2021;60:2413-7. [PMID: 33612684 DOI: 10.2169/internalmedicine.6707-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Verma A, Varma S, Freedberg DE, Axelrad JE. A Simple Emergency Department-Based Score Predicts Complex Hospitalization in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 33606139 DOI: 10.1007/s10620-021-06877-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Teixeira FV, Hosne RS, Sobrado CW. Management of ulcerative colitis: a clinical update. Journal of Coloproctology 2021;35:230-7. [DOI: 10.1016/j.jcol.2015.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
87 Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Rodríguez C, Elosua A, Prieto C, Pérez E, Irisarri R, Campillo A, Rubio S, Nantes Ó, Angós R, Zozaya JM. Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort. Gastroenterol Hepatol 2021:S0210-5705(21)00003-0. [PMID: 33545242 DOI: 10.1016/j.gastrohep.2020.11.016] [Reference Citation Analysis]
89 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
90 Li JR, Ling FM, Chen YD, Xu MY, Zhu LR. Treatment of acute severe ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2021; 29(2): 87-92 [DOI: 10.11569/wcjd.v29.i2.87] [Reference Citation Analysis]
91 Sedano R, Jairath V. High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. Inflamm Bowel Dis 2021;27:e59-60. [PMID: 33484120 DOI: 10.1093/ibd/izaa357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Calafat M, Mañosa M, Cañete F, Domènech E. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs Aging 2021;38:193-203. [PMID: 33438138 DOI: 10.1007/s40266-020-00832-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Sahu P, Kedia S, Vuyyuru SK, Bajaj A, Markandey M, Singh N, Singh M, Kante B, Kumar P, Ranjan M, Sahni P, Panwar R, Sharma R, Das P, Makharia G, Travis SPL, Ahuja V. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment Pharmacol Ther 2021;53:568-76. [PMID: 33440046 DOI: 10.1111/apt.16249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum. 2020;63:1028-1052. [PMID: 32692069 DOI: 10.1097/dcr.0000000000001716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
95 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
96 Mishra S, Mandavdhare HS, Singh H, Choudhury A, Shah J, Ram S, Kalsi D, Samanta J, Prasad KK, Sharma AK, Dutta U, Sharma V. Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial. Expert Rev Anti Infect Ther 2021;19:949-55. [PMID: 33245002 DOI: 10.1080/14787210.2021.1856656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
97 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
98 George LA, Cross RK. Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). Gastroenterology Clinics of North America 2020;49:705-16. [DOI: 10.1016/j.gtc.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
100 Lloyd K, Papoutsopoulou S, Smith E, Stegmaier P, Bergey F, Morris L, Kittner M, England H, Spiller D, White MHR, Duckworth CA, Campbell BJ, Poroikov V, Martins Dos Santos VAP, Kel A, Muller W, Pritchard DM, Probert C, Burkitt MD; SysmedIBD Consortium. Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease. Dis Model Mech 2020;13:dmm044040. [PMID: 32958515 DOI: 10.1242/dmm.044040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
101 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
102 Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021;6:38-47. [PMID: 33850838 DOI: 10.1159/000511296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
103 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
104 McDonnell M, Harris RJ, Borca F, Mills T, Downey L, Dharmasiri S, Patel M, Zare B, Stammers M, Smith TR, Felwick R, Cummings JRF, Phan HTT, Gwiggner M. High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterol 2020;7:e000532. [PMID: 33187976 DOI: 10.1136/bmjgast-2020-000532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Juliao-Baños F, Arrubla M, Osorio L, Camargo J, Londoño J, Cáceres C, Carvajal J, Mosquera-Klinger G, Donado J. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia. Gastroenterol Hepatol 2021;44:398-404. [PMID: 33172691 DOI: 10.1016/j.gastrohep.2020.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Horio Y, Uchino M, Bando T, Sasaki H, Goto Y, Kuwahara R, Minagawa T, Takesue Y, Ikeuchi H. Incidence, Risk Factors and Outcomes of Cancer of the Anal Transitional Zone in Patients with Ulcerative Colitis. J Crohns Colitis 2020;14:1565-71. [PMID: 32365200 DOI: 10.1093/ecco-jcc/jjaa089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
107 Ollech JE, Avni-Biron I, Glick L, Haider H, Dalal SR, Micic D, Pekow J, Yanai H, Cohen RD, Dotan I, Rubin DT, Sakuraba A. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31493-2. [PMID: 33223497 DOI: 10.1016/j.cgh.2020.10.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Hylander E, Hansen NE, Karle H, Janrum S. Serum Lysozyme in Crohn’s Disease and Ulcerative Colitis. Scandinavian Journal of Gastroenterology 1976;11:213-7. [DOI: 10.1080/00365521.1976.12097097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
109 Jensen KB, Jarnum S, Koudahl G, Kristensen M. Serum Orosomucoid in Ulcerative Colitis: Its Relation to Clinical Activity, Protein Loss, and Turnover of Albumin and IgG. Scandinavian Journal of Gastroenterology 1976;11:177-83. [DOI: 10.1080/00365521.1976.12097092] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
110 Kamel S, Sakr M, Hamed W, Eltabbakh M, Askar S, Bassuny A, Hussein R, Elbaz A. Comparative study between bowel ultrasound and magnetic resonance enterography among Egyptian inflammatory bowel disease patients. World J Gastroenterol 2020; 26(38): 5884-5895 [PMID: 33132642 DOI: 10.3748/wjg.v26.i38.5884] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Masnadi Shirazi K, Sotoudeh S, Masnadi Shirazi A, Moaddab SY, Nourpanah Z, Nikniaz Z. Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: A randomized, double-blind controlled clinical trial. Clin Res Hepatol Gastroenterol 2021;45:101532. [PMID: 33067169 DOI: 10.1016/j.clinre.2020.08.010] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
112 Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2020;69:1769-77. [PMID: 32513653 DOI: 10.1136/gutjnl-2020-321927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
113 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
114 Kakimoto K, Matsuura M, Fukuchi T, Hongo H, Kimura T, Aoyama N, Okuda Y, Aomatsu K, Kamata N, Yokoyama Y, Mizuno C, Inoue T, Miyazaki T, Nakamura S, Higuchi K, Nakase H. Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial. Crohns Colitis 360 2020;2:otaa073. [PMID: 34192247 DOI: 10.1093/crocol/otaa073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Khan ZAW, Shetty S, Pai GC, Acharya KKV, Nagaraja R. Prevalence of low bone mineral density in inflammatory bowel disease and factors associated with it. Indian J Gastroenterol 2020;39:346-53. [PMID: 32940845 DOI: 10.1007/s12664-020-01048-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432-52. [PMID: 32920854 DOI: 10.1111/apt.15998] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
117 Nakase H, Hirano T, Wagatsuma K, Ichimiya T, Yamakawa T, Yokoyama Y, Hayashi Y, Hirayama D, Kazama T, Yoshii S, Yamano HO. Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. Dig Endosc. 2020;. [PMID: 32909283 DOI: 10.1111/den.13825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
118 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 206] [Article Influence: 26.0] [Reference Citation Analysis]
119 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
120 Yang H, Wu K, Zhang H, Owyang Q, Miao Y, Gu F, Hu N, Zou K, Sheng J, Li J, Zheng P, Liu Y, Li J, Wang X, Wu Y, Yuan Y, Chen C, Pang Y, Cui M, Qian J. IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis. BMC Gastroenterol 2020;20:294. [PMID: 32891125 DOI: 10.1186/s12876-020-01434-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
121 Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000544. [PMID: 32856298 DOI: 10.1002/14651858.CD000544.pub5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
122 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
123 Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res 2021;19:323-31. [PMID: 32806875 DOI: 10.5217/ir.2020.00039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543. [PMID: 32786164 DOI: 10.1002/14651858.CD000543.pub5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
125 Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, Galiano MT, Barraza M, Molano J, Álvarez E, Corrales R, Vargas LE, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J; Grupo del Registro Colombiano de Enfermedad Inflamatoria Intestinal., Grupo Registro Colombiano de Enfermedad Inflamatoria Intestinal. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Rev Gastroenterol Mex (Engl Ed) 2021;86:153-62. [PMID: 32723624 DOI: 10.1016/j.rgmx.2020.05.005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Ollech JE, Normatov I, Peleg N, Dalal SR, Pekow J, Micic D, Cohen RD, Rubin DT, Sakuraba A. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis 2020;35:2113-6. [PMID: 32710391 DOI: 10.1007/s00384-020-03703-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Higashiyama M, Komoto S, Suzuki Y, Watanabe M, Hibi T, Miura S, Hokari R. Relation of geriatric nutritional risk index with clinical risks in elderly-onset ulcerative colitis. J Gastroenterol Hepatol 2021;36:163-70. [PMID: 32583472 DOI: 10.1111/jgh.15161] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Honap S, Pavlidis P, Ray S, Sharma E, Anderson S, Sanderson JD, Mawdsley J, Samaan MA, Irving PM. Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience. Inflamm Bowel Dis 2020;26:e147-9. [PMID: 32566937 DOI: 10.1093/ibd/izaa157] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
129 Furfaro F, Vuitton L, Fiorino G, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, Danese S, Peyrin-Biroulet L. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020;17:507-516. [PMID: 32528139 DOI: 10.1038/s41575-020-0319-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
130 Levy LC, Coburn ES, Choi S, Holubar SD. The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum. Current Opinion in Gastroenterology 2020;36:265-76. [DOI: 10.1097/mog.0000000000000637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Bolia R, Rajanayagam J, Hardikar W, Alex G. Impact of Changing Treatment Strategies on Outcomes in Pediatric Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1838-44. [PMID: 31002341 DOI: 10.1093/ibd/izz072] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
132 Sebastian S, Myers S, Argyriou K, Martin G, Los L, Fiske J, Ranjan R, Cooper B, Goodoory V, Ching HL, Jayasooriya N, Brooks J, Dhar A, Shenoy AH, Limdi JK, Butterworth J, Allen PB, Samuel S, Moran GW, Shenderey R, Parkes G, Lobo A, Kennedy NA, Subramanian S, Raine T. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019;50:675-683. [PMID: 31456297 DOI: 10.1111/apt.15456] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
133 Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, Fryer E, Collantes E, Sacco JJ, Pirmohamed M, Simmons A, Klenerman P, Tuthill M, Protheroe AS, Chitnis M, Fairfax BP, Payne MJ, Middleton MR, Brain O. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020;123:207-15. [PMID: 32418993 DOI: 10.1038/s41416-020-0882-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
134 Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
135 Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: From historical perspectives to emerging investigations. Int Wound J 2020;17:1255-65. [PMID: 32378319 DOI: 10.1111/iwj.13389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
136 de Alvarenga Antunes CV, de Alvarenga Nascimento CR, Campanha da Rocha Ribeiro T, de Alvarenga Antunes P, de Andrade Chebli L, Martins Gonçalves Fava L, Malaguti C, Maria Fonseca Chebli J. Treatment of iron deficiency anemia with liposomal iron in inflammatory bowel disease: efficacy and impact on quality of life. Int J Clin Pharm 2020;42:895-902. [PMID: 32367457 DOI: 10.1007/s11096-020-01044-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
137 Salameh R, Kirchgesner J, Allez M, Carbonnel F, Meyer A, Gornet JM, Beaugerie L, Amiot A. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther 2020;51:1096-104. [PMID: 32342994 DOI: 10.1111/apt.15751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
138 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
139 Rönnblom A, Karlbom U. Acute severe attacks of ulcerative colitis in a population-based cohort: epidemiology, treatment and outcome. Scandinavian Journal of Gastroenterology 2020;55:555-9. [DOI: 10.1080/00365521.2020.1757143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Yamamoto-Furusho JK, Mendieta-Escalante EA. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. PLoS One 2020;15:e0231988. [PMID: 32315368 DOI: 10.1371/journal.pone.0231988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
141 Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
142 Li H, Tian F. Toxic Epidermal Necrolysis Because of Various Herpesviruses Infection After Accelerated Infliximab Induction in a Chinese Patient With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2020;26:e38-40. [PMID: 32086936 DOI: 10.1093/ibd/izaa034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Lenti MV, Mengoli C, Vernero M, Aronico N, Conti L, Borrelli de Andreis F, Cococcia S, Di Sabatino A. Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease. Front Immunol 2020;11:485. [PMID: 32269571 DOI: 10.3389/fimmu.2020.00485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
144 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
146 Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
147 Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:6923609. [PMID: 32308714 DOI: 10.1155/2020/6923609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
148 Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther 2020;51:852-60. [PMID: 32201971 DOI: 10.1111/apt.15680] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
149 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
150 Syal G, Robbins L, Kashani A, Bonthala N, Feldman E, Fleshner P, Vasiliauskas E, McGovern D, Ha C, Targan S, Melmed GY. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis. Dig Dis Sci 2021;66:199-205. [PMID: 32170473 DOI: 10.1007/s10620-020-06177-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
151 Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;3:CD005573. [PMID: 32128795 DOI: 10.1002/14651858.CD005573.pub3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
152 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Obara Y, Komatsu M, Sugawara T. Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. Perm J 2019;23. [PMID: 31050638 DOI: 10.7812/TPP/18-220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
153 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
154 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
155 Lage AC, Oliveira CC, Batalha APDB, Araújo AF, Czuber-dochan W, Chebli JMF, Cabral LA, Malaguti C. THE INFLAMMATORY BOWEL DISEASE-FATIGUE PATIENT SELF-ASSESSMENT SCALE: TRANSLATION, CROSS-CULTURAL ADAPTATION AND PSYCHOMETRIC PROPERTIES OF THE BRAZILIAN VERSION (IBD-F BRAZIL). Arq Gastroenterol 2020;57:50-63. [DOI: 10.1590/s0004-2803.202000000-10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Yamamoto T, Carvello M, Lightner AL, Spinelli A, Kotze PG. Up-to-date surgery for ulcerative colitis in the era of biologics. Expert Opin Biol Ther. 2020;20:391-398. [PMID: 31948294 DOI: 10.1080/14712598.2020.1718098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Le Baut G, Kirchgesner J, Amiot A, Lefevre JH, Chafai N, Landman C, Nion I, Bourrier A, Delattre C, Martineau C, Sokol H, Seksik P, Nguyen Y, Marion Y, Lebreton G, Carbonnel F, Viennot S, Beaugerie L; Saint Antoine IBD Network. A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1602-1610.e1. [PMID: 31927106 DOI: 10.1016/j.cgh.2019.12.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
158 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
159 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 122] [Article Influence: 33.5] [Reference Citation Analysis]
160 O'Connell J, Keohane S, McGreal-Bellone A, McDonagh P, Naimimohasses S, Kennedy U, Dunne C, Hartery K, Larkin J, MacCarthy F, Meaney J, McKiernan S, Norris S, O'Toole D, Kevans D. Characteristics and outcomes of acute colitis diagnosed on cross-sectional imaging presenting via the emergency department in an Irish academic medical centre. Ir J Med Sci 2020;189:1115-21. [PMID: 31925651 DOI: 10.1007/s11845-019-02162-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT. Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020;18:1346-1355. [PMID: 31927105 DOI: 10.1016/j.cgh.2019.12.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
162 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 101] [Article Influence: 27.0] [Reference Citation Analysis]
163 Javad Hosseinzadeh-attar M, Sharifi A, Nedjat S, Mohamadkhani A, Vahedi H. The Effect of Vitamin D on Serum Asymmetric Dimethylarginine in Patients with Mild to Moderate Ulcerative Colitis. International Journal for Vitamin and Nutrition Research 2020;90:17-22. [DOI: 10.1024/0300-9831/a000303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
164 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
165 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
166 Xu M, Cen M, Chen X, Chen H, Liu X, Cao Q. Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease. Biomed Res Int 2019;2019:6517549. [PMID: 31950048 DOI: 10.1155/2019/6517549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
167 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 444] [Article Influence: 100.0] [Reference Citation Analysis]
168 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
169 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
170 Yılmaz İ, Dolar ME, Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial. Turk J Gastroenterol 2019;30:242-53. [PMID: 30662004 DOI: 10.5152/tjg.2018.18227] [Cited by in Crossref: 31] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
171 D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
172 Cao Q, Huang YH, Jiang M, Dai C. The prevalence and risk factors of psychological disorders, malnutrition and quality of life in IBD patients. Scand J Gastroenterol 2019;54:1458-66. [PMID: 31791216 DOI: 10.1080/00365521.2019.1697897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
173 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 555] [Article Influence: 205.7] [Reference Citation Analysis]
174 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 117] [Article Influence: 30.7] [Reference Citation Analysis]
175 Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7:49-55. [PMID: 32232203 DOI: 10.14744/nci.2018.78800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
176 Bertani L, Bodini G, Mumolo MG, de Bortoli N, Ceccarelli L, Frazzoni L, Tapete G, Albano E, Plaz Torres MC, Bellini M, Savarino E, Savarino V, Marchi S, Costa F. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Dig Dis Sci 2020;65:2397-402. [DOI: 10.1007/s10620-019-05959-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
177 Jovanovic M, Simovic Markovic B, Gajovic N, Jurisevic M, Djukic A, Jovanovic I, Arsenijevic N, Lukic A, Zdravkovic N. Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression. World J Gastroenterol 2019; 25(43): 6465-6482 [PMID: 31798282 DOI: 10.3748/wjg.v25.i43.6465] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
178 Hébuterne X, Peyrin-Biroulet L, Hausfater P. The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report. Dig Liver Dis 2020;52:420-6. [PMID: 31734114 DOI: 10.1016/j.dld.2019.10.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Sedano R, Quera R, Simian D, Yarur AJ. An approach to acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:943-55. [PMID: 31648574 DOI: 10.1080/17474124.2019.1681974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
180 Straughan DM, McLoughlin KC, Mullinax JE, Marciano BE, Freeman AF, Anderson VL, Uzel G, Azoury SC, Sorber R, Quadri HS, Malech HL, DeRavin SS, Kamal N, Koh C, Zerbe CS, Kuhns DB, Gallin JI, Heller T, Holland SM, Rudloff U. The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. Clin Infect Dis 2018;66:1427-34. [PMID: 29145578 DOI: 10.1093/cid/cix1012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
181 Rapport F, Clement C, Seagrove AC, Alrubaiy L, Hutchings HA, Williams JG. Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial. BMC Gastroenterol 2019;19:166. [PMID: 31615445 DOI: 10.1186/s12876-019-1085-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
182 Patrick D, Doecke JD, Irwin J, Hanigan K, Simms LA, Howlett M, Radford-Smith GL. Short-term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with co-ordinated transfer and tertiary care. Intern Med J 2020;50:823-9. [PMID: 31589361 DOI: 10.1111/imj.14649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Tam V, Schwartz M, Holder-Murray J, Salgado Pogacnik J. Change in paradigm: impact of an IBD medical home on the outpatient management of acute severe ulcerative colitis. BMJ Case Rep 2019;12:e230491. [PMID: 31586953 DOI: 10.1136/bcr-2019-230491] [Reference Citation Analysis]
184 Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, Martin ST, Buckley M, Sheridan J, Horgan G, Mulcahy HE, Cullen G, Doherty GA. CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis. J Clin Gastroenterol 2018;52:e48-52. [PMID: 28737646 DOI: 10.1097/MCG.0000000000000884] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
185 Caliskan Z, Tatlisu MA, Kahraman R, Gokturk S, Sayar S, Kostek O, Kul S, Baycan OF, Ozcan FG, Caliskan M. The Impact of Prognostic Nutritional Index on Coronary Flow Reserve in Patients with Inflammatory Bowel Disease. Medeni Med J 2019;34:271-7. [PMID: 32821448 DOI: 10.5222/MMJ.2019.47108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
186 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
187 Goldstone RN, Steinhagen RM. Abdominal Emergencies in Inflammatory Bowel Disease.Surg Clin North Am. 2019;99:1141-1150. [PMID: 31676053 DOI: 10.1016/j.suc.2019.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
188 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
189 Landerholm K, Kalman D, Wallon C, Myrelid P. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease? CDT 2019;20:1384-98. [DOI: 10.2174/1389450120666190617163919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
190 Sgambato D, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, Miranda A, De Mauro D, Romano L, Iolascon G, Romano M. Bone alterations in inflammatory bowel diseases. World J Clin Cases 2019; 7(15): 1908-1925 [PMID: 31423424 DOI: 10.12998/wjcc.v7.i15.1908] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
191 Rajan R, Trinder MW, Lo J, Theophilus M. Assessing the efficacy of TNF-alpha inhibitors in preventing emergency and emergent colectomies. JGH Open 2020;4:140-4. [PMID: 32280756 DOI: 10.1002/jgh3.12229] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
192 Negreanu L, Voiosu T, State M, Voiosu A, Bengus A, Mateescu BR. Endoscopy in inflammatory bowel disease: from guidelines to real life. Therap Adv Gastroenterol. 2019;12:1756284819865153. [PMID: 31384307 DOI: 10.1177/1756284819865153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
193 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. Revista de Gastroenterología de México (English Edition) 2019;84:317-25. [DOI: 10.1016/j.rgmxen.2019.02.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validación de un nuevo índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. Revista de Gastroenterología de México 2019;84:317-25. [DOI: 10.1016/j.rgmx.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
195 Dreesen E, Gils A. Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. Ther Drug Monit 2019;41:131-41. [PMID: 30883507 DOI: 10.1097/FTD.0000000000000571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Chen X, Yang K, Xu Y, Li K. Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. Medicine (Baltimore) 2019;98:e15718. [PMID: 31096525 DOI: 10.1097/MD.0000000000015718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
197 Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol 2019;54:707-11. [PMID: 31136207 DOI: 10.1080/00365521.2019.1620326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
198 Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol 2019; 25(18): 2240-2250 [PMID: 31143074 DOI: 10.3748/wjg.v25.i18.2240] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
199 Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology 2019;27:465-73. [PMID: 31054010 DOI: 10.1007/s10787-019-00595-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 46] [Article Influence: 9.7] [Reference Citation Analysis]
200 Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:557-61. [PMID: 30947569 DOI: 10.1080/17474124.2019.1604219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
201 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
202 Kang HS, Koo JS, Lee KM, Kim DB, Lee JM, Kim YJ, Yoon H, Jang HJ. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J Gastroenterol 2019; 25(8): 989-1001 [PMID: 30833804 DOI: 10.3748/wjg.v25.i8.989] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
203 Ben Jemaa S, Chtourou L, Akrout R, Chaabouni K, Chaabouni T, Fourati HM, Amouri A, Tahri N, Ayedi F, Baklouti S. Bone Mineral Density and Bone Remodeling in Tunisian Patients with Inflammatory Bowel Disease. TORJ 2019;13:22-9. [DOI: 10.2174/1874312901913010022] [Reference Citation Analysis]
204 López-Cortés R, Herrero-Hahn R, De la Rosa-Eduardo R, Montoya-Juárez R, García-Caro MP, Marín-Fernández B, Hueso-Montoro C. Cultural Adaptation and Validation of the Inflammatory Bowel Disease Disability Index in a Spanish Population and Its Association with Sociodemographic and Clinical Factors. Int J Environ Res Public Health 2019;16:E635. [PMID: 30795550 DOI: 10.3390/ijerph16040635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
205 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
206 Vasudevan A, Arachchi A, Scanlon C, Greenhalgh J, Van Langenberg DR. A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy. Ther Adv Chronic Dis 2019;10:2040622319825595. [PMID: 30728932 DOI: 10.1177/2040622319825595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
207 Hossen I, Hua W, Ting L, Mehmood A, Jingyi S, Duoxia X, Yanping C, Hongqing W, Zhipeng G, Kaiqi Z, Fang Y, Junsong X. Phytochemicals and inflammatory bowel disease: a review. Crit Rev Food Sci Nutr 2020;60:1321-45. [PMID: 30729797 DOI: 10.1080/10408398.2019.1570913] [Cited by in Crossref: 23] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
208 Rodríguez-lago I, Ferreiro-iglesias R, Nos P, Gisbert JP. Manejo de la colitis ulcerosa aguda grave en España: Resultados de una encuesta sobre práctica clínica. Gastroenterología y Hepatología 2019;42:90-101. [DOI: 10.1016/j.gastrohep.2018.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
209 Delgado ME, Brunner T. The many faces of tumor necrosis factor signaling in the intestinal epithelium. Genes Immun 2019;20:609-26. [DOI: 10.1038/s41435-019-0057-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
210 Imbrizi MR, Magro DO, Secundo TML, Cunha-Silva M, Kotze PG, Montes CG, Almeida JRS, Cabral VLR. Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients. Intest Res 2019;17:63-9. [PMID: 30678446 DOI: 10.5217/ir.2018.00077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
211 Okayasu M, Ogata H, Yoshiyama Y. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. J Mark Access Health Policy 2019;7:1565889. [PMID: 30719244 DOI: 10.1080/20016689.2019.1565889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
212 Ferrara G, Petrillo MG, Giani T, Marrani E, Filippeschi C, Oranges T, Simonini G, Cimaz R. Clinical Use and Molecular Action of Corticosteroids in the Pediatric Age. Int J Mol Sci 2019;20:E444. [PMID: 30669566 DOI: 10.3390/ijms20020444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
213 Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA 2019;321:156-64. [PMID: 30644982 DOI: 10.1001/jama.2018.20046] [Cited by in Crossref: 321] [Cited by in F6Publishing: 316] [Article Influence: 107.0] [Reference Citation Analysis]
214 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
215 Calixto RP, Flores C, Francesconi CF. Inflammatory bowel disease: impact on scores of quality of life, depression and anxiety in patients attending a tertiary care center in brazil. Arq Gastroenterol. 2018;55:202-207. [PMID: 30540078 DOI: 10.1590/s0004-2803.201800000-54] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
216 Qiu Y, Chen B, Li Y, Xiong S, Zhang S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. BMC Gastroenterol 2019;19:7. [PMID: 30630426 DOI: 10.1186/s12876-018-0928-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
217 Motobayashi M, Matsuoka K, Takenaka K, Fujii T, Nagahori M, Ohtsuka K, Iwamoto F, Tsuchiya K, Negi M, Eishi Y, Watanabe M. Predictors of mucosal healing during induction therapy in patients with acute moderate‐to‐severe ulcerative colitis. Journal of Gastroenterology and Hepatology 2018;34:1004-10. [DOI: 10.1111/jgh.14565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
218 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Yamada K, Sugawara T. Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. Perm J 2018;22:17-167. [PMID: 30005726 DOI: 10.7812/TPP/17-167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
219 Wu HM, Wei J, Li J, Wang K, Ye L, Qi Y, Yuan BS, Yang YL, Zhao L, Yang Z, Yang MF, Gong JF, Wang FY. Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis. Dig Dis Sci 2019;64:3263-73. [PMID: 30604378 DOI: 10.1007/s10620-018-5446-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
220 Kim SY, Mun EC, Chung J, Ha M, Ahn S, Han M, Han S, Yun S, Kim JH, Kim KO, Kim YJ, Kwon KA, Park DK. Increased genomic damage and vitamin B status in inflammatory bowel disease patients: A case-control, prospective, pilot study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2019;837:42-7. [DOI: 10.1016/j.mrgentox.2018.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
221 Xia D, An J. Serum folic acid, PCT, CRP and ESR detection as biomarker in differentiation ulcerative colitis activity. Pteridines 2018;29:179-86. [DOI: 10.1515/pteridines-2018-0016] [Reference Citation Analysis]
222 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 783] [Article Influence: 170.5] [Reference Citation Analysis]
223 Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:748-64. [PMID: 30576644 DOI: 10.1053/j.gastro.2018.12.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 91] [Article Influence: 16.0] [Reference Citation Analysis]
224 Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:769-808.e29. [PMID: 30576642 DOI: 10.1053/j.gastro.2018.12.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
225 Leoncini G, Villanacci V, Marin MG, Crisafulli V, Cadei M, Antonelli E, Leoci C, Bassotti G. Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. Tech Coloproctol. 2018;22:941-946. [PMID: 30535522 DOI: 10.1007/s10151-018-1896-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
226 Sampietro GM, Colombo F, Frontali A, Baldi CM, Carmagnola S, Cassinotti A, Dell’era A, Massari A, Molteni P, Dilillo D, Fociani P, Tonolini M, Maconi G, Fiorina P, Corsi F, Bianco R, Nebuloni M, Zuccotti G, Ardizzone S, Foschi D. Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results. Digestive and Liver Disease 2018;50:1283-91. [DOI: 10.1016/j.dld.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
227 Patrick D, Doecke J, Irwin J, Hanigan K, Simms L, Howlett M, Radford-Smith G. The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. Therap Adv Gastroenterol 2018;11:1756284818809789. [PMID: 30455743 DOI: 10.1177/1756284818809789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Landerholm K, Wood C, Bloemendaal A, Buchs N, George B, Guy R. The rectal remnant after total colectomy for colitis - intra-operative,post-operative and longer-term considerations. Scand J Gastroenterol. 2018;53:1443-1452. [PMID: 30451043 DOI: 10.1080/00365521.2018.1529195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
229 Berinstein JA, Steiner CA, Regal RE, Allen JI, Kinnucan JAR, Stidham RW, Waljee AK, Bishu S, Aldrich LB, Higgins PDR. Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:988-990.e1. [PMID: 30458248 DOI: 10.1016/j.cgh.2018.11.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
230 Chen D, Ma J, Luo S, Lu L, Wan X, Ben Q. Effects of Appendectomy on the Onset and Course of Ulcerative Colitis in Chinese Patients. Gastroenterol Res Pract 2018;2018:2927891. [PMID: 30524476 DOI: 10.1155/2018/2927891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
231 Neubauer K, Woźniak-Stolarska B, Krzystek-Korpacka M. Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results. Biomed Res Int 2018;2018:4961753. [PMID: 30515402 DOI: 10.1155/2018/4961753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
232 Wu D, Yang Z, Zhao C, Yao L. Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12657. [PMID: 30313056 DOI: 10.1097/MD.0000000000012657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
233 Chohno T, Uchino M, Sasaki H, Bando T, Takesue Y, Ikeuchi H. Associations Between the Prognostic Nutritional Index and Morbidity/Mortality During Intestinal Resection in Patients with Ulcerative Colitis. World J Surg 2018;42:1949-59. [PMID: 29270654 DOI: 10.1007/s00268-017-4411-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
234 Harris KG, Chang EB. The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. Clin Sci (Lond) 2018;132:2013-28. [PMID: 30232239 DOI: 10.1042/CS20171110] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
235 Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
236 Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. J Crohns Colitis 2018;12:289-97. [PMID: 29121178 DOI: 10.1093/ecco-jcc/jjx146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
237 Scribano ML, Papi C, Costa F, Bortoli A, Bortoluzzi F, Buscarini E, Cappello M, Caserta L, Cortelezzi C, Ferronato A, Manguso F, Mazzuoli S, Orzes N, Kohn A; AIGO IBD Study Group. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. Dig Liver Dis 2019;51:346-51. [PMID: 30195815 DOI: 10.1016/j.dld.2018.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
238 Pellet G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, Roblin X, Allimant C, Nachury M, Nancey S, Filippi J, Altwegg R, Brixi H, Fotsing G, de Rosamel L, Shili S, Laharie D; Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:494-501. [PMID: 30213584 DOI: 10.1016/j.cgh.2018.08.081] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
239 Haapamäki J, Heikkinen E, Sipponen T, Roine RP, Arkkila P. The impact of an adaptation course on health-related quality of life and functional capacity of patients with inflammatory bowel disease. Scand J Gastroenterol 2018;53:1074-8. [PMID: 30175636 DOI: 10.1080/00365521.2018.1500639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
240 Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818793558. [PMID: 30159037 DOI: 10.1177/1756284818793558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
241 Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
242 Li Y, Xu H, Xu T, Xiao M, Tang H, Wu D, Tan B, Li J, Yang H, Lv H, Xu Y, Qian J. Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus. Dig Dis Sci 2018;63:3074-83. [PMID: 30094621 DOI: 10.1007/s10620-018-5230-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
243 Singh S. Evolution of Clinical Trials in Inflammatory Bowel Diseases. Curr Gastroenterol Rep 2018;20:41. [PMID: 30078058 DOI: 10.1007/s11894-018-0648-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
244 Hanafy AS, Monir MH, Abdel Malak H, Desoky Aiad M. A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis. Inflamm Intest Dis 2018;3:16-24. [PMID: 30505838 DOI: 10.1159/000490795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
245 Hamanaka S, Nakagawa T, Hiwasa T, Ohta Y, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Matsumura T, Takizawa H, Kashiwado K, Kobayashi S, Matsushita K, Matsubara H, Katsuno T, Arai M, Kato N. Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis. Journal of Gastroenterology and Hepatology 2018;33:1975-83. [DOI: 10.1111/jgh.14297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
246 Seah D, Choy MC, Gorelik A, Connell WR, Sparrow MP, Van Langenberg D, Hebbard G, Moore G, De Cruz P. Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. J Gastroenterol Hepatol 2018;33:226-31. [PMID: 28618062 DOI: 10.1111/jgh.13850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
247 Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
248 Sharifi A, Vahedi H, Nedjat S, Mohamadkhani A, Hosseinzadeh Attar MJ. Vitamin D Decreases Beck Depression Inventory Score in Patients with Mild to Moderate Ulcerative Colitis: A Double-Blind Randomized Placebo-Controlled Trial. Journal of Dietary Supplements 2018;16:541-9. [DOI: 10.1080/19390211.2018.1472168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
249 Vedamurthy A, Xu L, Luther J, Colizzo F, Garber JJ, Khalili H, Ananthakrishnan AN. Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. Dig Dis Sci 2018;63:2740-6. [PMID: 29951797 DOI: 10.1007/s10620-018-5176-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
250 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
251 Tun GS, Harris A, Lobo AJ. Ulcerative colitis: management in adults, children and young people - concise guidance . Clin Med (Lond) 2017;17:429-33. [PMID: 28974592 DOI: 10.7861/clinmedicine.17-5-429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
252 Sahin A, Artas H, Eroglu Y, Tunc N, Oguz G, Demirel U, Poyrazoglu OK, Yalniz M, Bahcecioglu IH. A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes. J Clin Med 2018;7:E142. [PMID: 29890635 DOI: 10.3390/jcm7060142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Komoto S, Higashiyama M, Watanabe C, Suzuki Y, Watanabe M, Hibi T, Takebayashi T, Asakura K, Nishiwaki Y, Miura S, Hokari R. Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan. J Gastroenterol Hepatol 2018;33:1839-43. [PMID: 29669163 DOI: 10.1111/jgh.14263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
254 Severs M, Mangen MJ, Fidder HH, van der Valk ME, van der Have M, van Bodegraven AA, Clemens CHM, Dijkstra G, Jansen JM, de Jong DJ, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Romberg-Camps MJL, Siersema PD, Jharap B, van der Woude JC, Zuithoff NPA, Oldenburg B. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1568-76. [PMID: 28700534 DOI: 10.1097/MIB.0000000000001201] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
255 Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 31.8] [Reference Citation Analysis]
256 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
257 Akar M, Aydin F, Yurci MA, Abay S, Ateş İ, Deniz K. The possible relationship between Campylobacter spp./Arcobacter spp. and patients with ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2018;30:531-8. [DOI: 10.1097/meg.0000000000001095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
258 Lobo JL, Garcia-fuertes JA, Trujillo-santos J, Merah A, Blanco-molina MÁ, Casado I, Hirmerova J, De Miguel J, Salgado E, Monreal M. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease: . European Journal of Gastroenterology & Hepatology 2018;30:526-30. [DOI: 10.1097/meg.0000000000001084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
259 Urbano APS, Sassaki LY, Dorna MS, Presti PT, Carvalhaes MABL, Martini LA, Ferreira ALA. Associations among body composition, inflammatory profile and disease extent in ulcerative colitis patients.Rev Assoc Med Bras (1992). 2018;64:133-139. [PMID: 29641662 DOI: 10.1590/1806-9282.64.02.133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
260 Ribiere S, Leconte M, Chaussade S, Abitbol V. [Acute severe colitis]. Presse Med 2018;47:312-9. [PMID: 29618409 DOI: 10.1016/j.lpm.2018.02.020] [Reference Citation Analysis]
261 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Revista de Gastroenterología de México (English Edition) 2018;83:144-67. [DOI: 10.1016/j.rgmxen.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
262 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de Gastroenterología de México 2018;83:144-67. [DOI: 10.1016/j.rgmx.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
263 Vanga R, Long MD. Contemporary Management of Ulcerative Colitis. Curr Gastroenterol Rep. 2018;20:12. [PMID: 29589185 DOI: 10.1007/s11894-018-0622-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
264 Akintimehin AO, O'Neill RS, Ring C, Raftery T, Hussey S. Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis. Front Pediatr 2018;6:48. [PMID: 29568735 DOI: 10.3389/fped.2018.00048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
265 Sharifi A, Nedjat S, Vahedi H, Veghari G, Hosseinzadeh-Attar MJ. Vitamin D Status and Its Relation to Inflammatory Markers in Patients with Mild to Moderate Ulcerative Colitis. Middle East J Dig Dis 2018;10:84-9. [PMID: 30013756 DOI: 10.15171/mejdd.2018.95] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
266 Luo CX, Wen ZH, Zhen Y, Wang ZJ, Mu JX, Zhu M, Ouyang Q, Zhang H. Chinese research into severe ulcerative colitis has increased in quantity and complexity. World J Clin Cases 2018; 6(3): 35-43 [PMID: 29564356 DOI: 10.12998/wjcc.v6.i3.35] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
267 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
268 Cooke WT. Factors in the Management of Crohn's Disease: A Discussion Paper. J R Soc Med 1981;74:753-8. [DOI: 10.1177/014107688107401009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
269 Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, Sparrow MP, Connell WR, Moore GT, Radford-Smith G, Van Langenberg DR, De Cruz P. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol 2018;33:1347-52. [PMID: 29266456 DOI: 10.1111/jgh.14072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
270 Williams JG, Alam MF, Alrubaiy L, Clement C, Cohen D, Grey M, Hilton M, Hutchings HA, Longo M, Morgan JM, Rapport FL, Seagrove AC, Watkins A. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technol Assess 2016;20:1-320. [PMID: 27329657 DOI: 10.3310/hta20440] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
271 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
272 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 252] [Cited by in F6Publishing: 214] [Article Influence: 63.0] [Reference Citation Analysis]
273 Ritchie EA. Toxic Psychosis Under Cortisone and Corticotrophin. J ment sci 1956;102:830-7. [DOI: 10.1192/bjp.102.429.830] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
274 Kanauchi O, Mitsuyama K, Araki Y. Development of a Functional Germinated Barley Foodstuff from Brewer's Spent Grain for the Treatment of Ulcerative Colitis. Journal of the American Society of Brewing Chemists 2018;59:59-62. [DOI: 10.1094/asbcj-59-0059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
275 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Lambert J, Mary JY, Louis E; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237-43. [PMID: 28053054 DOI: 10.1136/gutjnl-2016-313060] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 21.8] [Reference Citation Analysis]
276 Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Practice & Research Clinical Gastroenterology 2018;32-33:71-8. [DOI: 10.1016/j.bpg.2018.05.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
277 Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
278 Bálint A, Farkas K, Szepes Z, Nagy F, Szűcs M, Tiszlavicz L, Bor R, Milassin Á, Rutka M, Fábián A, Molnár T. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system. BMC Gastroenterol 2018;18:7. [PMID: 29310593 DOI: 10.1186/s12876-017-0725-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
279 Schmitz EMH, Boekema PJ, Straathof JWA, van Renswouw DC, Brunsveld L, Scharnhorst V, van de Poll MEC, Broeren MAC, Derijks LJJ. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47:356-363. [PMID: 29205444 DOI: 10.1111/apt.14453] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
280 Uzzan M, Cosnes J, Amiot A, Gornet J, Seksik P, Cotte E, Tiret E, Panis Y, Treton X. Long-term Follow-up After Ileorectal Anastomosis for Ulcerative Colitis: A GETAID/GETAID Chirurgie Multicenter Retrospective Cohort of 343 Patients. Annals of Surgery 2017;266:1029-34. [DOI: 10.1097/sla.0000000000002022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
281 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
282 Cesarini M, Collins GS, Rönnblom A, Santos A, Wang LM, Sjöberg D, Parkes M, Keshav S, Travis SP. Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. J Crohns Colitis 2017;11:335-41. [PMID: 27647858 DOI: 10.1093/ecco-jcc/jjw159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
283 Chen D, Luo S, Ben Q, Lu L, Wan X, Wu J. Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China. Eur J Gastroenterol Hepatol. 2017;29:509-515. [PMID: 28350740 DOI: 10.1097/meg.0000000000000838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
284 Sawada K. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease. Transfus Apher Sci 2017;56:689-97. [PMID: 28986009 DOI: 10.1016/j.transci.2017.08.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
285 Siow VS, Bhatt R, Mollen KP. Management of acute severe ulcerative colitis in children. Semin Pediatr Surg. 2017;26:367-372. [PMID: 29126505 DOI: 10.1053/j.sempedsurg.2017.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
286 Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol 2017; 23(36): 6628-6638 [PMID: 29085208 DOI: 10.3748/wjg.v23.i36.6628] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 57] [Article Influence: 13.6] [Reference Citation Analysis]
287 Dudley-Brown S. Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. Gastroenterol Nurs 2017;40 Suppl 1S:S1-S14. [PMID: 27922458 DOI: 10.1097/SGA.0000000000000277] [Reference Citation Analysis]
288 Goyal A, Ghoshal UC, Nath A, Jindal S, Mohindra S. Pulmonary function in patients with ulcerative colitis and its relationship with disease severity. JGH Open 2017;1:32-7. [PMID: 30483530 DOI: 10.1002/jgh3.12005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
289 Saha SK, Panwar R, Kumar A, Pal S, Ahuja V, Dash NR, Makharia G, Sahni P. Early colectomy in steroid-refractory acute severe ulcerative colitis improves operative outcome. Int J Colorectal Dis. 2018;33:79-82. [PMID: 28920181 DOI: 10.1007/s00384-017-2903-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
290 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
291 Uchino M, Ikeuchi H, Sugita A, Futami K, Watanabe T, Fukushima K, Tatsumi K, Koganei K, Kimura H, Hata K, Takahashi K, Watanabe K, Mizushima T, Funayama Y, Higashi D, Araki T, Kusunoki M, Ueda T, Koyama F, Itabashi M, Nezu R, Suzuki Y; a research grant on intractable disease affiliated with the Japan Ministry of Health Labor Welfare. Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study. J Gastroenterol 2018;53:642-51. [PMID: 28884201 DOI: 10.1007/s00535-017-1389-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
292 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
293 Leeds IL, Truta B, Parian AM, Chen SY, Efron JE, Gearhart SL, Safar B, Fang SH. Early Surgical Intervention for Acute Ulcerative Colitis Is Associated with Improved Postoperative Outcomes. J Gastrointest Surg. 2017;21:1675-1682. [PMID: 28819916 DOI: 10.1007/s11605-017-3538-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
294 Iida T, Ikeya K, Kato M, Abe J, Yamamoto M, Watanabe F, Sugimoto K, Hanai H. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion. 2017;96:119-126. [PMID: 28796990 DOI: 10.1159/000479502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
295 Ren PW, Yang WJ, Wang DD, Shan JY, Kang DY, Hong Q, Wen S, Zhang RW. Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach. Evid Based Complement Alternat Med 2017;2017:6019530. [PMID: 28848616 DOI: 10.1155/2017/6019530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
296 Peyrin-biroulet L, Van Assche G, Armuzzi A, Garcia-alvarez L, Lara N, Black CM, Khalifa A, Cornillie F, Kachroo S. Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2017;15:1154-1161.e1. [DOI: 10.1016/j.cgh.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
297 Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. Ir J Med Sci 2018;187:385-92. [PMID: 28756540 DOI: 10.1007/s11845-017-1666-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
298 Fascì-Spurio F, Meucci G, Papi C, Saibeni S; IG-IBD (Italian Group for Inflammatory Bowel Disease). The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. Dig Liver Dis 2017;49:1092-7. [PMID: 28801181 DOI: 10.1016/j.dld.2017.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
299 Taks M, Pijls PA, Derijks LJ, Ten Broeke R, Grouls RJ, Curvers J, Gilissen LP. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2017;29:169-73. [PMID: 27749780 DOI: 10.1097/MEG.0000000000000763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
300 Shi HY, Chan FKL, Higashimori A, Kyaw M, Ching JYL, Chan HCH, Chan JCH, Chan AWH, Lam KLY, Tang RSY. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest Endosc. 2017;86:1139-1146.e6. [PMID: 28713062 DOI: 10.1016/j.gie.2017.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
301 Andrew RE, Lauria A, Puleo FJ, Berg A, Stewart DB Sr. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis. J Surg Res 2017;219:18-24. [PMID: 29078879 DOI: 10.1016/j.jss.2017.05.077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
302 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
303 Zhao Y, Wang J, Liu Z, Lin H, Shi Y, Sun X. Pulmonary dysfunction in 114 patients with inflammatory bowel disease. Medicine (Baltimore) 2017;96:e6808. [PMID: 28471982 DOI: 10.1097/MD.0000000000006808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
304 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
305 Khan N, Patel D, Shah Y, Lichtenstein G, Yang Y. A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:991-7. [DOI: 10.1097/mib.0000000000001080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
306 Mosli MH, Parker CE, Nelson SA, Baker KA, MacDonald JK, Zou GY, Feagan BG, Khanna R, Levesque BG, Jairath V. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2017;5:CD011256. [PMID: 28542712 DOI: 10.1002/14651858.CD011256.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
307 Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
308 Horio Y, Uchino M, Bando T, Chohno T, Sasaki H, Hirata A, Takesue Y, Ikeuchi H. Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies.BMC Surg. 2017;17:59. [PMID: 28526076 DOI: 10.1186/s12893-017-0255-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
309 Kalappurayil NB, Thomas J, Mankuni B, Thomas V. Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. J Clin Diagn Res 2017;11:EC07-11. [PMID: 28511386 DOI: 10.7860/JCDR/2017/22816.9332] [Reference Citation Analysis]
310 Yang YF, Zhou YD, Hu JC, Luo FL, Xie Y, Shen YY, Bian WX, Yin ZN, Li HL, Zhang XL. Ficolin-A/2, acting as a new regulator of macrophage polarization, mediates the inflammatory response in experimental mouse colitis. Immunology 2017;151:433-50. [PMID: 28380665 DOI: 10.1111/imm.12741] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
311 Kokkinidis DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, Texakalidis PT, Economopoulos KP, Kousoulis AA. Emerging treatments for ulcerative colitis: a systematic review. Scand J Gastroenterol 2017;52:923-31. [PMID: 28503977 DOI: 10.1080/00365521.2017.1326163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
312 Ozdil K, Caliskan Z, Keles N, Ozturk O, Tekin AS, Kahraman R, Doganay L, Demircioglu K, Yilmaz Y, Caliskan M. Echocardiographic epicardial fat thickness measurement: A new screening test for subclinic atherosclerosis in patients with inflammatory bowel diseases. North Clin Istanb 2017;4:4-12. [PMID: 28752137 DOI: 10.14744/nci.2017.74508] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
313 Buchs NC, Bloemendaal ALA, Wood CPJ, Travis S, Mortensen NJ, Guy RJ, George BD. Subtotal colectomy for ulcerative colitis: lessons learned from a tertiary centre. Colorectal Dis 2017;19:O153-61. [DOI: 10.1111/codi.13658] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
314 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
315 Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice. World J Gastroenterol 2017; 23(16): 2995-3002 [PMID: 28522918 DOI: 10.3748/wjg.v23.i16.2995] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
316 Zhao X, Zhou C, Ma J, Zhu Y, Sun M, Wang P, Zhang Y, Ma H, Zhang H. Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Sci Rep 2017;7:46693. [PMID: 28440311 DOI: 10.1038/srep46693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
317 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
318 Pawlica-Gosiewska D, Solnica B, Gawlik K, Cibor D, Mach T, Fedak D, Owczarek D. The use of selected neutrophil protein plasma concentrations in the diagnosis of Crohn's disease and ulcerative colitis - a preliminary report. Postepy Hig Med Dosw (Online) 2017;71:243-53. [PMID: 28397705 DOI: 10.5604/01.3001.0010.3810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
319 Mege D, Monsinjon M, Zappa M, Stefanescu C, Treton X, Maggiori L, Bouhnik Y, Panis Y. Is abdominal CT useful for the management of patients with severe acute colitis complicating inflammatory bowel disease? A study in 54 consecutive patients. Colorectal Dis 2017;19:O97-O102. [DOI: 10.1111/codi.13640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
320 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
321 Bhattacharyya S, Shumard T, Xie H, Dodda A, Varady KA, Feferman L, Halline AG, Goldstein JL, Hanauer SB, Tobacman JK. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging 2017;4:181-92. [PMID: 28447072 DOI: 10.3233/NHA-170023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
322 Uchino M, Ikeuchi H, Bando T, Chohno T, Sasaki H, Horio Y. Is An Ostomy Rod Useful for Bridging the Retraction During the Creation of a Loop Ileostomy? A Randomized Control Trial. World J Surg 2017;41:2128-35. [DOI: 10.1007/s00268-017-3978-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
323 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
324 Carr RM, Patel A, Bownik H, Oranu A, Kerner C, Praestgaard A, Forde KA, Reddy KR, Lichtenstein GR. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. Dig Dis Sci. 2017;62:1354-1361. [PMID: 28265826 DOI: 10.1007/s10620-017-4495-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
325 Vainer B, Nielsen OH. Correlation between Circulating Soluble ICAM-1 and Prednisolone-induced Amelioration of Ulcerative Colitis. Scandinavian Journal of Gastroenterology 2017;38:283-7. [DOI: 10.1080/00365520310000609a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
326 Smolinska A, Bodelier AG, Dallinga JW, Masclee AA, Jonkers DM, van Schooten FJ, Pierik MJ. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis. Aliment Pharmacol Ther 2017;45:1244-54. [PMID: 28239876 DOI: 10.1111/apt.14004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
327 Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017;33:82-88. [PMID: 28612022 DOI: 10.1159/000458006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
328 Figueredo CM, Martins AP, Lira-Junior R, Menegat JB, Carvalho AT, Fischer RG, Gustafsson A. Activity of inflammatory bowel disease influences the expression of cytokines in gingival tissue. Cytokine 2017;95:1-6. [PMID: 28189042 DOI: 10.1016/j.cyto.2017.01.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
329 Rai T, Choudhury BN, Kedia S, Bopanna S, Venigalla PM, Garg SK, Singla V, Makharia G, Ahuja V. Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. Dig Dis Sci. 2017;62:1025-1034. [PMID: 28161855 DOI: 10.1007/s10620-017-4450-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
330 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
331 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 566] [Article Influence: 98.4] [Reference Citation Analysis]
332 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
333 Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801-813. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 13.4] [Reference Citation Analysis]
334 Franceschet I, Cazzagon N, Del Ross T, D'Incà R, Buja A, Floreani A. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. Eur J Gastroenterol Hepatol 2016;28:508-13. [PMID: 26872110 DOI: 10.1097/MEG.0000000000000596] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
335 Wu H, Sun L, Lin DP, Shao XX, Xia SL, Lv M. Association of Fucosyltransferase 2 Gene Polymorphisms with Inflammatory Bowel Disease in Patients from Southeast China. Gastroenterol Res Pract 2017;2017:4148651. [PMID: 28167958 DOI: 10.1155/2017/4148651] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
336 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
337 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
338 Fornaro R, Caratto E, Caratto M, Sticchi C, Salerno A, Bianchi R, Scabini S, Casaccia M. Surgery of acute severe ulcerative colitis. Subtotal colectomy: when and how to do it? Eur Surg 2017;49:108-12. [DOI: 10.1007/s10353-016-0458-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
339 Gisbert JP, Barreiro-de Acosta M, Esteve M, García-Sánchez V, Gomollón F, Guardiola J, Hinojosa J, Martín Arranz MD, Minguez M, Taxonera C, Vera I. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflamm Bowel Dis 2016;22:583-98. [PMID: 26529561 DOI: 10.1097/MIB.0000000000000617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
340 Bodelier AG, Jonkers D, van den Heuvel T, de Boer E, Hameeteman W, Masclee AA, Pierik MJ. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. Dig Dis Sci. 2017;62:465-472. [PMID: 27933473 DOI: 10.1007/s10620-016-4397-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
341 Deiana S, Bagnoli S, Manetti N, Caini S, Giannotta M, Scaringi S, Annese V. Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Digestive and Liver Disease 2016;48:1432-7. [DOI: 10.1016/j.dld.2016.07.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
342 Okita Y, Araki T, Kondo S, Fujikawa H, Yoshiyama S, Hiro J, Inoue M, Toiyama Y, Kobayashi M, Ohi M, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Clinical Characteristics of Stoma-Related Obstruction after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. J Gastrointest Surg 2017;21:554-9. [PMID: 27896653 DOI: 10.1007/s11605-016-3329-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
343 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
344 Moura FA, de Andrade KQ, de Araújo OR, Nunes-Souza V, Santos JC, Rabelo LA, Goulart MO. Colonic and Hepatic Modulation by Lipoic Acid and/or N-Acetylcysteine Supplementation in Mild Ulcerative Colitis Induced by Dextran Sodium Sulfate in Rats. Oxid Med Cell Longev 2016;2016:4047362. [PMID: 27957238 DOI: 10.1155/2016/4047362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
345 Dong K, Zhang H, Yan Y, Sun J, Dong Y, Wang K, Zhang L, Shi X, Xing J. Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate. Drug Dev Ind Pharm 2017;43:448-57. [PMID: 27819157 DOI: 10.1080/03639045.2016.1258410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
346 Zhang T, Ding C, Xie T, Yang J, Dai X, Lv T, Li Y, Gu L, Wei Y, Gong J, Zhu W, Li N, Li J. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. Clin Nutr. 2017;36:1586-1592. [PMID: 27814937 DOI: 10.1016/j.clnu.2016.10.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
347 Hovde Ø, Småstuen MC, Høivik ML, Bernklev T, Huppertz-Hauss G, Høie O, Jahnsen J, Stray N, Henriksen M, Solberg IC, Moum BA. Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study. Inflamm Bowel Dis 2016;22:141-5. [PMID: 26355464 DOI: 10.1097/MIB.0000000000000582] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
348 Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558-567. [PMID: 26315728 DOI: 10.1111/1751-2980.12278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
349 Yu Q, Mao R, Lian L, Ng SC, Zhang S, Chen Z, Zhang Y, Qiu Y, Chen B, He Y, Zeng Z, Ben-Horin S, Song X, Chen M. Surgical management of inflammatory bowel disease in China: a systematic review of two decades. Intest Res 2016;14:322-32. [PMID: 27799883 DOI: 10.5217/ir.2016.14.4.322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
350 Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
351 Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016;111:1692-1701. [PMID: 27725645 DOI: 10.1038/ajg.2016.418] [Cited by in Crossref: 77] [Cited by in F6Publishing: 91] [Article Influence: 12.8] [Reference Citation Analysis]
352 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
353 D'haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther 2016;44:1018-29. [DOI: 10.1111/apt.13803] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
354 Stansfield C. Considerations in the management of ulcerative colitis. Gastrointestinal Nursing 2016;14:42-50. [DOI: 10.12968/gasn.2016.14.7.42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
355 Truelove SC. Treatment of Ulcerative Colitis with Local Hydrocortisone. Proceedings of the Royal Society of Medicine 2016;51:429-31. [DOI: 10.1177/003591575805100608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
356 Shah SC, Colombel J, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1245-1255.e8. [DOI: 10.1016/j.cgh.2016.01.015] [Cited by in Crossref: 159] [Cited by in F6Publishing: 152] [Article Influence: 26.5] [Reference Citation Analysis]
357 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 11.2] [Reference Citation Analysis]
358 Lennard-jones JE, Longmore AJ, Jones FA. A Comparative Trial of Salazopyrin Prednisone and Hydrocortisone Retention Enemata in the Out-Patient Treatment of Left-Sided Colitis. Preliminary Report. Proceedings of the Royal Society of Medicine 2016;53:647-50. [DOI: 10.1177/003591576005300817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
359 Mcewan HP. Anorectal Conditions in Obstetric Practice: Ulcerative Colitis in Pregnancy. Proceedings of the Royal Society of Medicine 2016;65:279-81. [DOI: 10.1177/003591577206500324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
360 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
361 Lin WC, Tung CC, Lin HH, Lin CC, Chang CW, Yen HH, Chuang CH, Hsu WH, Tsai WS, Wang HY, Lin JK, Wei SC, Wong JM. Elderly Adults with Late-Onset Ulcerative Colitis Tend to Have Atypical, Milder Initial Clinical Presentations but Higher Surgical Rates and Mortality: A Taiwan Society of Inflammatory Bowel Disease Study. J Am Geriatr Soc 2016;64:e95-7. [PMID: 27564225 DOI: 10.1111/jgs.14427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
362 Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
363 Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol 2016;3:e000103. [PMID: 27648296 DOI: 10.1136/bmjgast-2016-000103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
364 Caliskan Z, Keles N, Gokturk HS, Ozdil K, Aksu F, Ozturk O, Kahraman R, Kostek O, Tekin AS, Ozgur GT, Caliskan M. Is activation in inflammatory bowel diseases associated with further impairment of coronary microcirculation? Int J Cardiol 2016;223:176-81. [PMID: 27541650 DOI: 10.1016/j.ijcard.2016.08.141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
365 Popp C, Nichita L, Voiosu T, Bastian A, Cioplea M, Micu G, Pop G, Sticlaru L, Bengus A, Voiosu A, Mateescu RB. Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis. Dis Markers 2016;2016:3625279. [PMID: 27578918 DOI: 10.1155/2016/3625279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
366 Okita Y, Araki T, Hiro J, Ide S, Imaoka H, Kondo S, Kawamura M, Fujikawa H, Inoue M, Toiyama Y. Systemic Acute-phase Response in Laparoscopic and Open Ileal Pouch Anal Anastomosis in Patients With Ulcerative Colitis: A Case-matched Comparative Study. Surg Laparosc Endosc Percutan Tech. 2015;25:424-429. [PMID: 25730740 DOI: 10.1097/sle.0000000000000128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
367 Zhang T, Lin QY, Fei JX, Zhang Y, Lin MY, Jiang SH, Wang P, Chen Y. Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease. Sci Rep 2016;6:29791. [PMID: 27417996 DOI: 10.1038/srep29791] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
368 Tsuchiya M, Miura S, Asakura H, Hibi T, Tanaka T, Aiso S, Hiramatsu K. Angiographic Evaluation of Vascular Changes in Ulcerative Colitis. Angiology 1980;31:147-53. [DOI: 10.1177/000331978003100301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
369 Iacucci M, Panaccione R. Recent advances in the endoscopic assessment of ulcerative colitis. Techniques in Gastrointestinal Endoscopy 2016;18:116-22. [DOI: 10.1016/j.tgie.2016.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
370 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016;48:703-8. [DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
371 Hanan IM, Hanauer SB. Fulminant Colitis and Toxic Megacolon. J Intensive Care Med 1988;3:164-70. [DOI: 10.1177/088506668800300305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
372 Alrubaiy L, Rikaby I, Sageer M, Hutchings HA, Williams JG. Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2460-6. [PMID: 25966838 DOI: 10.1097/MIB.0000000000000438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
373 Kim ES, Chen M, Lee J, Lee CK, Kim YS. Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res 2016;14:224-30. [PMID: 27433144 DOI: 10.5217/ir.2016.14.3.224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
374 Lin CC, Wei SC, Lin BR, Tsai WS, Chen JS, Hsu TC, Lin WC, Huang TY, Chao TH, Lin HH, Wong JM, Lin JK. A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. Intest Res 2016;14:248-57. [PMID: 27433147 DOI: 10.5217/ir.2016.14.3.248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
375 Wayne EJ. Clinical Surveys and Clinical Trials. Scott Med J 1957;2:51-6. [DOI: 10.1177/003693305700200201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
376 Giacomelli R, Passacantando A, Parzanese I, Cucinelli F, Klidara N, Lattanzio R, Santori E, Paolini F, Manetti L, D'alo S, Cipriani P, Cifone M, Tonietti G. γ/δ T Cells are not Involved in the Natural and Antibody-Dependent Cytotoxicity of Peripheral blood Mononuclear Cells in Inflammatory Bowel Disease. Int J Immunopathol Pharmacol 1997;10:183-8. [DOI: 10.1177/039463209701000303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
377 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
378 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
379 Ghadir MR, Bagheri M, Vahedi H, Ebrahimi Daryani N, Malekzadeh R, Hormati A, Kolahdoozan S, Chaharmahali M. Nonadherence to Medication in Inflammatory Bowel Disease: Rate and Reasons. Middle East J Dig Dis 2016;8:116-21. [PMID: 27252818 DOI: 10.15171/mejdd.2016.16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
380 Kucharski M, Karczewski J, Mańkowska-wierzbicka D, Karmelita-katulska K, Grzymisławski M, Kaczmarek E, Iwanik K, Rzymski P, Swora-cwynar E, Linke K, Dobrowolska A. Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2016;28:722-30. [DOI: 10.1097/meg.0000000000000601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
381 Menegat JSB, Lira-junior R, Siqueira MA, Brito F, Carvalho AT, Fischer RG, Figueredo CM. Cytokine expression in gingival and intestinal tissues of patients with periodontitis and inflammatory bowel disease: An exploratory study. Archives of Oral Biology 2016;66:141-6. [DOI: 10.1016/j.archoralbio.2016.02.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
382 Sharma P, Makharia G, Yadav R, Dwivedi SN, Deepak KK. Gastric myoelectrical activity in patients with inflammatory bowel disease. J Smooth Muscle Res 2015;51:50-7. [PMID: 26447103 DOI: 10.1540/jsmr.51.50] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
383 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
384 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
385 Bruckstein AH. New salicylate therapies for ulcerative colitis. Postgraduate Medicine 2016;88:79-89. [DOI: 10.1080/00325481.1990.11704726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
386 Efe TH, Cimen T, Ertem AG, Coskun Y, Bilgin M, Sahan HF, Pamukcu HE, Yayla C, Sunman H, Yuksel I, Yeter E. Atrial Electromechanical Properties in Inflammatory Bowel Disease. Echocardiography. 2016;33:1309-1316. [PMID: 27158773 DOI: 10.1111/echo.13261] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
387 Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;CD000544. [PMID: 27158764 DOI: 10.1002/14651858.cd000544.pub4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
388 Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;:CD000544. [PMID: 27158764 DOI: 10.1002/14651858.CD000544.pub4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
389 Carlberg DJ, Lee SD, Dubin JS. Lower Abdominal Pain. Emerg Med Clin North Am 2016;34:229-49. [PMID: 27133242 DOI: 10.1016/j.emc.2015.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
390 Waterman M, Knight J, Dinani A, Xu W, Stempak JM, Croitoru K, Nguyen GC, Cohen Z, McLeod RS, Greenberg GR, Steinhart AH, Silverberg MS. Predictors of Outcome in Ulcerative Colitis. Inflamm Bowel Dis 2015;21:2097-105. [PMID: 26177304 DOI: 10.1097/MIB.0000000000000466] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
391 García-López S, Bocos JM, Gisbert JP, Bajador E, Chaparro M, Castaño C, García-Erce JA, Gomollón F. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016;14:199-205. [PMID: 27177405 DOI: 10.2450/2016.0246-15] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
392 Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543. [PMID: 27101467 DOI: 10.1002/14651858.cd000543.pub4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
393 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Chow WH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry. Therap Adv Gastroenterol. 2016;9:449-456. [PMID: 27366213 DOI: 10.1177/1756283x16643509] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
394 Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-horin S. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 2016;43:1293-9. [DOI: 10.1111/apt.13631] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
395 Pineton de Chambrun G, Blanc P, Peyrin-biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2016. [DOI: 10.1586/17474124.2016.1174064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
396 Kuwahara E, Murakami Y, Nakamura T, Inoue N, Nagahori M, Matsui T, Watanabe M, Suzuki Y, Nishiwaki Y. Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J Gastroenterol 2017;52:185-93. [PMID: 27075755 DOI: 10.1007/s00535-016-1209-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
397 Solina G, Mandalà S, La Barbera C, Mandalà V. Current management of intestinal bowel disease: the role of surgery. Updates Surg 2016;68:13-23. [PMID: 27067590 DOI: 10.1007/s13304-016-0361-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
398 Fron C, Pierry C, Poullenot F, Chabrun E, Subtil C, Capdepont M, Zerbib F, Belleannée G, Laharie D. Endoscopic and histologic response to cyclosporine in ulcerative colitis and their impact on disease outcome: A cohort study. Dig Liver Dis 2016;48:734-9. [PMID: 27052254 DOI: 10.1016/j.dld.2016.03.007] [Reference Citation Analysis]
399 Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA). Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients. Intern Med J 2015;45:659-66. [PMID: 25732268 DOI: 10.1111/imj.12732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
400 Hosseini SV, Taghavi SA, Jafari P, Rezaianzadeh A, Moini M, Mehrabi M, Sepehrimanesh M, Safarpour AR. Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran. Ann Colorectal Res 2016;4. [DOI: 10.17795/acr-34565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
401 Hirayama Y, Ando T, Hirooka Y, Watanabe O, Miyahara R, Nakamura M, Yamamura T, Goto H. Characteristic endoscopic findings and risk factors for cytomegalovirus-associated colitis in patients with active ulcerative colitis. World J Gastrointest Endosc 2016; 8(6): 301-309 [PMID: 27014426 DOI: 10.4253/wjge.v8.i6.301] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
402 Lawrance IC. Acute severe ulcerative colitis: Changing treatment paradigms. J Gastroenterol Hepatol 2016;31 Suppl 1:16. [PMID: 26991023 DOI: 10.1111/jgh.13350] [Reference Citation Analysis]
403 Musci JO, Cornish JS, Däbritz J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 2016;51:531-47. [PMID: 26975751 DOI: 10.1007/s00535-016-1191-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
404 Tambuwala MM. Natural Nuclear Factor Kappa Beta Inhibitors: Safe Therapeutic Options for Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2016;22:719-23. [DOI: 10.1097/mib.0000000000000655] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
405 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 220] [Cited by in F6Publishing: 198] [Article Influence: 36.7] [Reference Citation Analysis]
406 Kim JH, Cheon JH, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 2016;51:1069-74. [PMID: 26895215 DOI: 10.3109/00365521.2016.1150503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
407 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
408 Hosseini SV, Safarpour AR, Taghavi SA. Developing a novel risk-scoring system for predicting relapse in patients with ulcerative colitis: A prospective cohort study. Pak J Med Sci. 2015;31:1511-1516. [PMID: 26870126 DOI: 10.12669/pjms.316.8811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
409 Lee NS, Pola S, Groessl EJ, Rivera-Nieves J, Ho SB. Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Dig Dis Sci 2016;61:1003-12. [PMID: 26860508 DOI: 10.1007/s10620-016-4046-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
410 Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
411 Marín-jiménez I, Nos P, Domènech E, Riestra S, Gisbert JP, Calvet X, Cortés X, Iglesias E, Huguet JM, Taxonera C, Fernández R, Carpio D, Gutiérrez A, Guardiola J, Laria LC, Sicilia B, Bujanda L, Cea-calvo L, Romero C, Rincón Ó, Juliá B, Panés J. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. American Journal of Gastroenterology 2016;111:261-8. [DOI: 10.1038/ajg.2015.403] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
412 Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
413 Mikocka-Walus A, Pittet V, Rossel JB, von Känel R. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2016;14:829-835.e1. [PMID: 26820402 DOI: 10.1016/j.cgh.2015.12.045] [Cited by in Crossref: 191] [Cited by in F6Publishing: 184] [Article Influence: 31.8] [Reference Citation Analysis]
414 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
415 Clemente V, Aratari A, Papi C, Vernia P. Short term colectomy rate and mortality for severe ulcerative colitis in the last 40 years. Has something changed? Dig Liver Dis 2016;48:371-5. [PMID: 26854257 DOI: 10.1016/j.dld.2015.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
416 Hu D, Zhang D, Zheng S, Guo M, Lin X, Jiang Y. Association of Ulcerative Colitis with FUT2 and FUT3 Polymorphisms in Patients from Southeast China. PLoS One. 2016;11:e0146557. [PMID: 26766790 DOI: 10.1371/journal.pone.0146557] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
417 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
418 Zhai H, Liu A, Huang W, Liu X, Feng S, Wu J, Yao Y, Wang C, Li Q, Hao Q, Hu J, Zhang S. Increasing rate of inflammatory bowel disease: a 12-year retrospective study in NingXia, China. BMC Gastroenterol 2016;16:2. [PMID: 26754840 DOI: 10.1186/s12876-015-0405-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
419 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
420 Shapiro JM, Hagin SE, Shah SA, Bright R, Law M, Moniz H, Giacalone J, Jackvony T, Taleban S, Samad Z. Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. Dig Dis Sci. 2016;61:1635-1640. [PMID: 26725063 DOI: 10.1007/s10620-015-4010-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
421 Wu XR, Liu XL, Katz S, Shen B. Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. Inflamm Bowel Dis. 2015;21:703-715. [PMID: 25687266 DOI: 10.1097/mib.0000000000000227] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
422 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 75] [Article Influence: 9.1] [Reference Citation Analysis]
423 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
424 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
425 Kini AT, Thangaraj KR, Simon E, Shivappagowdar A, Thiagarajan D, Abbas S, Ramachandran A, Venkatraman A. Aberrant Niche Signaling in the Etiopathogenesis of Ulcerative Colitis: . Inflammatory Bowel Diseases 2015;21:2549-61. [DOI: 10.1097/mib.0000000000000523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
426 Baker ME. Acute Infectious and Inflammatory Enterocolitides. Radiologic Clinics of North America 2015;53:1255-71. [DOI: 10.1016/j.rcl.2015.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
427 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Wong SH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Tong RW, Chow WH, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry. J Crohns Colitis 2016;10:176-85. [PMID: 26512132 DOI: 10.1093/ecco-jcc/jjv194] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
428 Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
429 Dai YC, Zhang YL, Wang LJ, Guo Q, Yang K, Ye RH, Tang ZP. Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients. Chin J Integr Med. 2016;22:811-816. [PMID: 26501692 DOI: 10.1007/s11655-015-2118-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
430 Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2015;27:242-248. [PMID: 25569569 DOI: 10.1097/meg.0000000000000279] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
431 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
432 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
433 Øresland T, Faerden AE. Surgery in the age of biological treatment. Scand J Gastroenterol 2015;50:121-7. [PMID: 25523562 DOI: 10.3109/00365521.2014.972445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
434 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
435 Selvaggi F, Pellino G, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Tech Coloproctol 2015;19:627-38. [PMID: 26386867 DOI: 10.1007/s10151-015-1367-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
436 Wang Y, MacDonald JK, Benchimol EI, Griffiths AM, Steinhart AH, Panaccione R, Seow CH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;CD006790. [PMID: 26368001 DOI: 10.1002/14651858.cd006790.pub3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
437 Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. J Intern Med. 2016;279:241-258. [PMID: 26355194 DOI: 10.1111/joim.12413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
438 Bjarnason I, Hayee B, Pavlidis P, Kvasnovsky C, Scalori A, Sisson G, Charlesworth A, Shaikh H, Bjornsson E, Heneghan MA. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis. EBioMedicine 2015;2:1523-7. [PMID: 26629548 DOI: 10.1016/j.ebiom.2015.08.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
439 Freitas TH, Hyphantis TN, Andreoulakis E, Quevedo J, Miranda HL, Alves GS, Souza MH, Braga LL, Pargament KI, Soczynska JK, Mcintyre RS, Carvalho AF. Religious coping and its influence on psychological distress, medication adherence, and quality of life in inflammatory bowel disease. Braz J Psychiatry 2015;37:219-27. [DOI: 10.1590/1516-4446-2014-1507] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
440 Chen G, Cao S, Liu F, Liu Y. miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. Biochem J 2015;471:357-67. [PMID: 26303523 DOI: 10.1042/BJ20150095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
441 dos Santos LC, Costa AV, Lopes LG, Leonel AJ, Aguilar EC, Noviello Mde L, Ferrari Mde L, Alvarez-Leite JI. Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation. Med Sci Monit 2015;21:2305-15. [PMID: 26252649 DOI: 10.12659/MSM.893865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
442 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
443 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
444 Jani K, Shah A. Laparoscopic total proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. J Minim Access Surg 2015;11:177-83. [PMID: 26195875 DOI: 10.4103/0972-9941.140212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
445 Solberg IC, Høivik ML, Cvancarova M, Moum B. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol. 2015;50:1456-1462. [PMID: 26139389 DOI: 10.3109/00365521.2015.1064991] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
446 Moses PL, Moore BR, Ferrentino N, Bensen SP, Vecchio JA. Inflammatory bowel disease: 1. Origins, presentation, and course. Postgraduate Medicine 2015;103:77-102. [DOI: 10.3810/pgm.1998.05.483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
447 Freitas TH, Andreoulakis E, Alves GS, Miranda HL, Braga LL, Hyphantis T, Carvalho AF. Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease. World J Gastroenterol 2015; 21(21): 6713-6727 [PMID: 26074710 DOI: 10.3748/wjg.v21.i21.6713] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
448 Aloi M, D’arcangelo G, Capponi M, Nuti F, Vassallo F, Civitelli F, Oliva S, Pagliaro G, Cucchiara S. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy. Digestive and Liver Disease 2015;47:455-9. [DOI: 10.1016/j.dld.2015.01.156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
449 Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014;20:1668-1677. [PMID: 24918319 DOI: 10.1097/mib.0000000000000087] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
450 Cortes X, Borrás-Blasco J, Molés JR, Boscá M, Cortés E. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study. PLoS One. 2015;10:e0128156. [PMID: 26011514 DOI: 10.1371/journal.pone.0128156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
451 Orabona R, Valcamonico A, Salemme M, Manenti S, Tiberio GA, Frusca T. Fulminant ulcerative colitis in a healthy pregnant woman. World J Gastroenterol 2015; 21(19): 6060-6064 [PMID: 26019473 DOI: 10.3748/wjg.v21.i19.6060] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
452 Lunney PC, Kariyawasam VC, Wang RR, Middleton KL, Huang T, Selinger CP, Andrews JM, Katelaris PH, Leong RW. Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2015;42:61-70. [PMID: 25968332 DOI: 10.1111/apt.13239] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
453 Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh 2015;87:34-8. [PMID: 25864346 DOI: 10.17116/terarkh201587234-38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
454 Hiraoka S, Kato J, Moritou Y, Takei D, Inokuchi T, Nakarai A, Takahashi S, Harada K, Okada H, Yamamoto K. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. BMC Gastroenterol. 2015;15:53. [PMID: 25925267 DOI: 10.1186/s12876-015-0285-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
455 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
456 Kraiem I, Hadhri S, Ben Rejeb M, Ifa L, Jmaa A, Ajmi S, Skouri H. Antiphospholipid Antibodies and Procoagulant Profile in Tunisians With Inflammatory Bowel Diseases. Clin Appl Thromb Hemost 2016;22:734-42. [PMID: 25878173 DOI: 10.1177/1076029615581364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
457 Samaan MA, Mosli MH, Sandborn WJ, Feagan BG, D' Haens GR, Dubcenco E, Baker KA, Levesque BG. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465-1471. [PMID: 24831558 DOI: 10.1097/mib.0000000000000046] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
458 Desai D, Shah S, Deshmukh A, Abraham P, Joshi A, Gupta T, Deshpande R, Khandagale V, George S. Colorectal cancers in ulcerative colitis from a low-prevalence area for colon cancer. World J Gastroenterol 2015; 21(12): 3644-3649 [PMID: 25834332 DOI: 10.3748/wjg.v21.i12.3644] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
459 Criscuoli V, Rizzuto MR, Gallo E, Orlando A, Cottone M. Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. J Clin Virol 2015;66:103-6. [PMID: 25866348 DOI: 10.1016/j.jcv.2015.03.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
460 Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L, Keshav S, Travis S. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis. 2015;9:376-381. [PMID: 25770163 DOI: 10.1093/ecco-jcc/jjv047] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
461 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
462 Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
463 Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology 2015;50:933-41. [DOI: 10.3109/00365521.2015.1018937] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
464 Slovak J, Wang C, Sun Y, Otoni C, Morrison J, Deitz K, Levine D, Jergens A. Development and validation of an endoscopic activity score for canine inflammatory bowel disease. The Veterinary Journal 2015;203:290-5. [DOI: 10.1016/j.tvjl.2014.12.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
465 Hosseini SV, Jafari P, Taghavi SA, Safarpour AR, Rezaianzadeh A, Moini M, Mehrabi M. Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J 2015;17:e22796. [PMID: 25793117 DOI: 10.5812/ircmj.22796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
466 Bryant R, Sandborn W, Travis S. Introducing Vedolizumab to Clinical Practice: Who, When, and How? Journal of Crohn's and Colitis 2015;9:356-66. [DOI: 10.1093/ecco-jcc/jjv033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
467 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
468 Antunes CV, Hallack Neto AE, Nascimento CR, Chebli LA, Moutinho IL, Pinheiro Bdo V, Reboredo MM, Malaguti C, Castro AC, Chebli JM. Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology. Biomed Res Int. 2015;2015:728925. [PMID: 25705682 DOI: 10.1155/2015/728925] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
469 Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cir Esp 2015;93:276-82. [PMID: 25649534 DOI: 10.1016/j.ciresp.2014.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
470 Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015;148:740-750.e2. [PMID: 25644096 DOI: 10.1053/j.gastro.2015.01.037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
471 Dige A, Støy S, Thomsen KL, Hvas CL, Agnholt J, Dahlerup JF, Møller HJ, Grønbaek H. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease. Scand J Immunol 2014;80:417-23. [PMID: 25346048 DOI: 10.1111/sji.12222] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
472 Yuan BS, Jin XX, Lu YK, Liu J, Wang SD, Wang ZK, Wu L, Wang FY. Clinical significance of serum procalcitonin in patients with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2015; 23(1): 37-43 [DOI: 10.11569/wcjd.v23.i1.37] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
473 Lee KJ. Pharmacologic treatment for inflammatory bowel disease. J Korean Med Assoc 2015;58:57. [DOI: 10.5124/jkma.2015.58.1.57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
474 Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M, Marteau P, Zmora O, Kotze PG, Espin-basany E, Tiret E, Sica G, Panis Y, Faerden AE, Biancone L, Angriman I, Serclova Z, de Buck van Overstraeten A, Gionchetti P, Stassen L, Warusavitarne J, Adamina M, Dignass A, Eliakim R, Magro F, D’hoore A. European evidence based consensus on surgery for ulcerative colitis. Journal of Crohn's and Colitis 2015;9:4-25. [DOI: 10.1016/j.crohns.2014.08.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 184] [Article Influence: 23.3] [Reference Citation Analysis]
475 Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID. Predicting outcomes in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:405-415. [PMID: 25494666 DOI: 10.1586/17474124.2015.992880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
476 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
477 Cai C, Shen J, Zhao D, Qiao Y, Xu A, Jin S, Ran Z, Zheng Q. Serological investigation of food specific immunoglobulin G antibodies in patients with inflammatory bowel diseases. PLoS One. 2014;9:e112154. [PMID: 25393003 DOI: 10.1371/journal.pone.0112154] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
478 Alrubaiy L, Dodds P, Hutchings HA, Russell IT, Watkins A, Williams JG. Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). Frontline Gastroenterol 2015;6:161-8. [PMID: 28839806 DOI: 10.1136/flgastro-2014-100530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
479 do Carmo AM, Santos FM, Ortiz-Agostinho CL, Nishitokukado I, Frota CS, Gomes FU, Leite AZ, Pannuti CS, Boas LS, Teixeira MG, Sipahi AM. Cytomegalovirus infection in inflammatory bowel disease is not associated with worsening of intestinal inflammatory activity. PLoS One 2014;9:e111574. [PMID: 25387236 DOI: 10.1371/journal.pone.0111574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
480 Fuss IJ, Joshi B, Yang Z, Degheidy H, Fichtner-Feigl S, de Souza H, Rieder F, Scaldaferri F, Schirbel A, Scarpa M, West G, Yi C, Xu L, Leland P, Yao M, Mannon P, Puri RK, Fiocchi C, Strober W. IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut 2014;63:1728-36. [PMID: 24515806 DOI: 10.1136/gutjnl-2013-305671] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
481 Hata K, Kazama S, Nozawa H, Kawai K, Kiyomatsu T, Tanaka J, Tanaka T, Nishikawa T, Yamaguchi H, Ishihara S. Laparoscopic surgery for ulcerative colitis: a review of the literature. Surg Today. 2015;45:933-938. [PMID: 25346254 DOI: 10.1007/s00595-014-1053-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
482 Xia SL, Yu LQ, Chen H, Hu DY, Shao XX, Guo MD, Jiang LJ, Lin XX, Lin XQ, Jiang Y. Association of vitamin D receptor gene polymorphisms with the susceptibility to ulcerative colitis in patients from Southeast China. J Recept Signal Transduct Res 2015;35:530-5. [PMID: 25347331 DOI: 10.3109/10799893.2014.975248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
483 Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564-75. [PMID: 24412993 DOI: 10.1097/01.MIB.0000437986.00190.71] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
484 Chi HG, Zheng XB, Wu ZG, Dai SX, Wan Z, Zou Y. Association of the interleukin-22 genetic polymorphisms with ulcerative colitis. Diagn Pathol 2014;9:183. [PMID: 25297677 DOI: 10.1186/s13000-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
485 Keerthy HK, Mohan CD, Siveen KS, Fuchs JE, Rangappa S, Sundaram MS, Li F, Girish KS, Sethi G, Basappa, Bender A, Rangappa KS. Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo. J Biol Chem 2014;289:31879-90. [PMID: 25231984 DOI: 10.1074/jbc.M114.593855] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
486 Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553-1563. [PMID: 25199861 DOI: 10.1016/j.mayocp.2014.07.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 15.9] [Reference Citation Analysis]
487 Samaan MA, Bagi P, Vande Casteele N, D’haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014;43:479-94. [DOI: 10.1016/j.gtc.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
488 Chae HB, Jung YS, Park DI, Lee CK, Huh KC, Shin JE, Kim JH, Kim YS, Jung Y, Jung SA, Song HJ, Jang HJ, Hong SN, Kim YH. [Differences in the prognosis according to the periods of diagnosis in ulcerative colitis]. Korean J Gastroenterol 2014;64:93-7. [PMID: 25168051 DOI: 10.4166/kjg.2014.64.2.93] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
489 Uchino M, Ikeuchi H, Matsuoka H, Takahashi Y, Tomita N, Takesue Y. Surgical site infection and validity of staged surgical procedure in emergent/urgent surgery for ulcerative colitis. Int Surg 2013;98:24-32. [PMID: 23438273 DOI: 10.9738/CC83.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
490 Caliskan Z, Gokturk HS, Caliskan M, Gullu H, Ciftci O, Ozgur GT, Guven A, Selcuk H. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease. Microvasc Res 2015;97:25-30. [PMID: 25128749 DOI: 10.1016/j.mvr.2014.08.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
491 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 17.8] [Reference Citation Analysis]
492 Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2014;20:14-20. [PMID: 24297054 DOI: 10.1097/01.MIB.0000437497.07181.05] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
493 Bodelier AG, Pierik MJ, van den Heuvel T, Bovee-oudenhoven IM, de Boer E, Hameeteman W, Masclee AA, Jonkers D. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients. European Journal of Gastroenterology & Hepatology 2014;26:902-9. [DOI: 10.1097/meg.0000000000000141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
494 Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, Mulcahy HE, Cullen G, Doherty GA. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335. e1. [PMID: 25086187 DOI: 10.1016/j.cgh.2014.07.041] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 20.0] [Reference Citation Analysis]
495 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
496 Maranville JC, Micic D, Hanauer SB, Di Rienzo A, Kupfer SS. In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014;8:1539-1547. [PMID: 25052346 DOI: 10.1016/j.crohns.2014.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
497 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
498 Ahmad H, Berzin TM, Yu HJ, Huang CS, Mishkin DS. Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf) 2014;2:201-6. [PMID: 24994835 DOI: 10.1093/gastro/gou033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
499 Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 2014;63:1092-102. [PMID: 24107590 DOI: 10.1136/gutjnl-2013-305600] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 11.5] [Reference Citation Analysis]
500 Walsh A, Palmer R, Travis S. Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. Gastrointestinal Endoscopy Clinics of North America 2014;24:367-78. [DOI: 10.1016/j.giec.2014.03.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
501 Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374-381. [PMID: 24961751 DOI: 10.1111/apt.12834] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
502 Olaisen M, Rydning A, Martinsen TC, Nordrum IS, Mjønes P, Fossmark R. Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. Scandinavian Journal of Gastroenterology 2014;49:845-52. [DOI: 10.3109/00365521.2014.929172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
503 Windsor A, Michetti P, Bemelman W, Ghosh S. The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. Inflamm Bowel Dis. 2013;19:2695-2703. [PMID: 23846487 DOI: 10.1097/mib.0b013e318292fae6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
504 Zhu S, Bing Y, Wang X, Yu Q, Wang Y, Xu S, Song L, Wang X, Xia B, Zhu Y, Zhou R. CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice. PLoS One 2014;9:e100167. [PMID: 24936795 DOI: 10.1371/journal.pone.0100167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
505 Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, Efremidou E, Kouklakis G. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol. 2014;49:942-949. [PMID: 24897131 DOI: 10.3109/00365521.2014.920910] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
506 Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:635-42. [PMID: 24887059 DOI: 10.1016/j.cgh.2014.03.037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
507 Deepak P, Bruining DH. Radiographical evaluation of ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:169-177. [PMID: 24843072 DOI: 10.1093/gastro/gou026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
508 Siegmund B. Ätiopathogenese chronisch-entzündlicher Darmerkrankungen: Rolle des Immunsystems. Internist 2014;55:883-8. [DOI: 10.1007/s00108-013-3440-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
509 Gecse KB, Lakatos PL. Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opinion on Pharmacotherapy 2014;15:1565-73. [DOI: 10.1517/14656566.2014.920322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
510 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
511 Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy: Anti-TNF therapy in ulcerative colitis. Intern Med J 2014;44:464-70. [DOI: 10.1111/imj.12397] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
512 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
513 Seagrove AC, Alam MF, Alrubaiy L, Cheung WY, Clement C, Cohen D, Grey M, Hilton M, Hutchings H, Morgan J. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). BMJ Open. 2014;4:e005091. [PMID: 24785401 DOI: 10.1136/bmjopen-2014-005091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
514 Alves RA, Miszputen SJ, Figueiredo MS. Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables. Sao Paulo Med J 2014;132:140-6. [PMID: 24760213 DOI: 10.1590/1516-3180.2014.1323568] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
515 Regan BP, Bousvaros A. Pediatric Ulcerative Colitis: A Practical Guide to Management. Pediatr Drugs 2014;16:189-98. [DOI: 10.1007/s40272-014-0070-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
516 Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
517 Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:622-30. [DOI: 10.1097/mib.0000000000000008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
518 Algaba A, Linares PM, Encarnación Fernández-contreras M, Figuerola A, Calvet X, Guerra I, de Pousa I, Chaparro M, Gisbert JP, Bermejo F. The Effects of Infliximab or Adalimumab on Vascular Endothelial Growth Factor and Angiopoietin 1 Angiogenic Factor Levels in Inflammatory Bowel Disease: Serial Observations in 37 Patients. Inflammatory Bowel Diseases 2014;20:695-702. [DOI: 10.1097/mib.0000000000000004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
519 Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5:803-815. [PMID: 23902548 DOI: 10.2217/imt.13.81] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
520 Freire P, Cardoso R, Figueiredo P, Donato MM, Ferreira M, Mendes S, Ferreira AM, Vasconcelos H, Portela F, Sofia C. NOD2 gene mutations in ulcerative colitis: useless or misunderstood? Int J Colorectal Dis. 2014;29:653-661. [PMID: 24651958 DOI: 10.1007/s00384-014-1850-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
521 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
522 Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095-1103. [PMID: 24641622 DOI: 10.1111/apt.12712] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
523 Kato K, Ohkusa T, Terao S, Chiba T, Murakami K, Yanaka A, Uehara T, Ishii Y, Soma M, Tajiri H. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2014;39:949-956. [PMID: 24628398 DOI: 10.1111/apt.12688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
524 Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9. [PMID: 23714676 DOI: 10.1097/MIB.0b013e3182874065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
525 Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflamm Bowel Dis 2013;19:2031-40. [PMID: 23811638 DOI: 10.1097/MIB.0b013e3182920108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
526 Han W, Xu J, Hu N, Mei Q, Liu M. Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. Scandinavian Journal of Gastroenterology 2014;49:424-33. [DOI: 10.3109/00365521.2014.886716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
527 Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn’s Disease. Drugs 2014;74:313-24. [DOI: 10.1007/s40265-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
528 Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5-22. [PMID: 24316941 DOI: 10.1097/dcr.0000000000000030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 92] [Article Influence: 13.4] [Reference Citation Analysis]
529 Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, Annese V, Riegler G, Orlando A, Viscido A. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis. 2014;8:852-858. [PMID: 24472490 DOI: 10.1016/j.crohns.2014.01.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
530 Ye BD. How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis? Dig Dis Sci 2014;59:706-7. [PMID: 24435183 DOI: 10.1007/s10620-013-2985-2] [Reference Citation Analysis]
531 Inokuchi T, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol 2014; 20(2): 509-517 [PMID: 24574719 DOI: 10.3748/wjg.v20.i2.509] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
532 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
533 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:395-405. [DOI: 10.1586/egh.09.24] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
534 Sehgal R, Koltun WA. Scoring systems in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;4:513-21. [DOI: 10.1586/egh.10.40] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
535 Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci 2014;59:829-37. [PMID: 24352705 DOI: 10.1007/s10620-013-2907-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
536 Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv and Transl Res 2014;4:187-202. [DOI: 10.1007/s13346-013-0185-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
537 Koido S, Ohkusa T, Takakura K, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Kajihara M, Uchiyama K, Arakawa H, Tajiri H. Clinical significance of serum procalcitonin in patients with ulcerative colitis. World J Gastroenterol 2013; 19(45): 8335-8341 [PMID: 24363525 DOI: 10.3748/wjg.v19.i45.8335] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
538 Song L, Zhou R, Huang S, Zhou F, Xu S, Wang W, Yi F, Wang X, Xia B. High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease. Mediators Inflamm 2013;2013:425915. [PMID: 24382939 DOI: 10.1155/2013/425915] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
539 Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51. [PMID: 23639092 DOI: 10.1586/egh.13.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
540 Mitsuyama K, Niwa M, Masuda J, Yamasaki H, Kuwaki K, Takedatsu H, Kobayashi T, Kinjo F, Kishimoto K, Matsui T, Hirai F, Makiyama K, Ohba K, Abe H, Tsubouchi H, Fujita H, Maekawa R, Yoshida H, Sata M; The Kyushu ACP Study Group. Possible diagnostic role of antibodies to Crohn’s disease peptide (ACP): results of a multicenter study in a Japanese cohort. J Gastroenterol 2014;49:683-91. [DOI: 10.1007/s00535-013-0916-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
541 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 466] [Article Influence: 54.0] [Reference Citation Analysis]
542 Dong X, Ye X, Chen X, Chen T, Xie S, Li Q, Lin X, Huang Z. Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease. Dig Dis Sci. 2014;59:769-777. [PMID: 24287641 DOI: 10.1007/s10620-013-2962-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
543 Chhaya V, Pollok R. The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference? F1000Prime Rep 2013;5:50. [PMID: 24273651 DOI: 10.12703/P5-50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
544 Bertin D, Grimaud JC, Lesavre N, Benelmouloud C, Desjeux A, Garcia S, Desplat-Jégo S. Targeting tissular immune response improves diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease. PLoS One 2013;8:e80433. [PMID: 24303014 DOI: 10.1371/journal.pone.0080433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
545 Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis. 2014;46:219-226. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
546 Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H; IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010;50 Suppl 1:S1-13. [PMID: 20081543 DOI: 10.1097/MPG.0b013e3181c92c53] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 11.2] [Reference Citation Analysis]
547 Freeman HJ. Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag. 2013;9:451-456. [PMID: 24235838 DOI: 10.2147/TCRM.S38852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
548 Kuwata G, Kamisawa T, Koizumi K, Tabata T, Hara S, Kuruma S, Fujiwara T, Chiba K, Egashira H, Fujiwara J, Arakawa T, Momma K, Horiguchi S. Ulcerative colitis and immunoglobulin G4. Gut Liver 2014;8:29-34. [PMID: 24516698 DOI: 10.5009/gnl.2014.8.1.29] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
549 Bartels SAL, Gardenbroek TJ, Bos L, Ponsioen CY, D'haens GRAM, Tanis PJ, Buskens CJ, Bemelman WA. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis. Colorectal Dis 2013;15:1392-8. [DOI: 10.1111/codi.12328] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
550 Iida T, Ikeya K, Watanabe F, Abe J, Maruyama Y, Ohata A, Teruyuki S, Sugimoto K, Hanai H. Looking for endoscopic features of cytomegalovirus colitis: a study of 187 patients with active ulcerative colitis, positive and negative for cytomegalovirus. Inflamm Bowel Dis. 2013;19:1156-1163. [PMID: 23619714 DOI: 10.1097/mib.0b013e31828075ce] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
551 Weber NK, Bruining DH, Loftus EV, Tremaine WJ, Augustin JJ, Becker BD, Kammer PP, Harmsen WS, Zinsmeister AR, Pardi DS. Comparative Outcomes of Younger and Older Hospitalized Patients with Inflammatory Bowel Disease Treated with Corticosteroids: . Inflammatory Bowel Diseases 2013;19:2644-51. [DOI: 10.1097/01.mib.0000436961.08029.17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
552 Park SH, Kim D, Ye BD, Yang SK, Kim JH, Yang DH, Jung KW, Kim KJ, Byeon JS, Myung SJ. The characteristics of ulcerative colitis associated with autoimmune pancreatitis. J Clin Gastroenterol. 2013;47:520-525. [PMID: 23426453 DOI: 10.1097/mcg.0b013e31827fd4a2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
553 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
554 Gu J, Stocchi L, Remzi FH, Kiran RP. Total abdominal colectomy for severe ulcerative colitis: does the laparoscopic approach really have benefit? Surg Endosc. 2014;28:617-625. [PMID: 24196546 DOI: 10.1007/s00464-013-3218-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
555 Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8:341-348. [PMID: 24094598 DOI: 10.1016/j.crohns.2013.09.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 78] [Article Influence: 7.9] [Reference Citation Analysis]
556 Portela F, Lago P. Fulminant colitis. Best Practice & Research Clinical Gastroenterology 2013;27:771-82. [DOI: 10.1016/j.bpg.2013.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
557 Bermejo F, Algaba A, Guerra I, Chaparro M, De-La-Poza G, Valer P, Piqueras B, Bermejo A, García-Alonso J, Pérez MJ. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients? Scand J Gastroenterol. 2013;48:1272-1277. [PMID: 24063425 DOI: 10.3109/00365521.2013.836752] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
558 Papi C, Fascì-Spurio F, Rogai F, Settesoldi A, Margagnoni G, Annese V. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis. 2013;45:978-985. [PMID: 24018244 DOI: 10.1016/j.dld.2013.07.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
559 Bordeianou L, Maguire L. State-of-the-Art Surgical Approaches to the Treatment of Medically Refractory Ulcerative Colitis. J Gastrointest Surg 2013;17:2013-9. [DOI: 10.1007/s11605-013-2312-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
560 Park SH, Yang SK, Hong SM, Park SK, Kim JW, Lee HJ, Yang DH, Jung KW, Kim KJ, Ye BD. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci. 2013;58:3592-3599. [PMID: 23979435 DOI: 10.1007/s10620-013-2828-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
561 Stobaugh DJ, Deepak P, Thorpe M, Hannon B, Ehrenpreis ED. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. Inflamm Bowel Dis. 2013;19:301-308. [PMID: 22644716 DOI: 10.1002/ibd.23003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
562 Soletti RC, Rodrigues NA, Biasoli D, Luiz RR, de Souza HS, Borges HL. Immunohistochemical analysis of retinoblastoma and β-catenin as an assistant tool in the differential diagnosis between Crohn's disease and ulcerative colitis. PLoS One 2013;8:e70786. [PMID: 23967107 DOI: 10.1371/journal.pone.0070786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
563 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 8.1] [Reference Citation Analysis]
564 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
565 Nakano R, Iwakiri R, Ikeda Y, Kishi T, Tsuruoka N, Shimoda R, Sakata Y, Yamaguchi K, Fujimoto K. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. J Gastroenterol Hepatol 2013;28:303-8. [PMID: 23339387 DOI: 10.1111/jgh.12049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
566 Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 89] [Article Influence: 8.7] [Reference Citation Analysis]
567 Alrubaiy L, Hutchings HA, Williams JG. Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open 2013;3:e003192. [PMID: 23842503 DOI: 10.1136/bmjopen-2013-003192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
568 Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-Sánchez M. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58:2949-2954. [PMID: 23828140 DOI: 10.1007/s10620-013-2762-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
569 Kawamura J, Hasegawa S, Kawada K, Yamaguchi T, Nagayama S, Matsusue R, Nomura A, Sakai Y. Feasibility and safety of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis for severe ulcerative colitis: Laparoscopy for severe UC. Asian J Endosc Surg 2013;6:271-8. [DOI: 10.1111/ases.12046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
570 Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963-2969. [PMID: 23812861 DOI: 10.1007/s10620-013-2748-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
571 Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther. 2013;38:294-302. [PMID: 23786158 DOI: 10.1111/apt.12375] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 7.7] [Reference Citation Analysis]
572 Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study. Inflammatory Bowel Diseases 2013;19:1384-9. [DOI: 10.1097/mib.0b013e318281325e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
573 Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [DOI: 10.1111/apt.12345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
574 Ujihara M, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Morise K, Maeda K, Matsushita M, Miyahara R, Ohmiya N, Nishio Y, Yamaguchi T, Haruta J, Ina K, Goto H. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes 2013;6:210. [PMID: 23706098 DOI: 10.1186/1756-0500-6-210] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
575 Miyoshi J, Matsuoka K, Inoue N, Hisamatsu T, Ichikawa R, Yajima T, Okamoto S, Naganuma M, Sato T, Kanai T, Ogata H, Iwao Y, Hibi T. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013;7:e609-e614. [PMID: 23680174 DOI: 10.1016/j.crohns.2013.04.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
576 Yeşil A, Gönen C, Senateş E, Paker N, Gökden Y, Koçhan K, Erdem ED, Gündüz F. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci 2013;58:2587-93. [PMID: 23633156 DOI: 10.1007/s10620-013-2676-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
577 Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, Tomita N, Takesue Y. Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis. Int J Colorectal Dis. 2013;28:1295-1306. [PMID: 23604447 DOI: 10.1007/s00384-013-1700-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
578 Dimitroulia E, Pitiriga VC, Piperaki ET, Spanakis NE, Tsakris A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum. 2013;56:322-327. [PMID: 23392146 DOI: 10.1097/dcr.0b013e31827cd02c] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
579 Masoodi I, Alsayari K, Albishri J. Inflammatory bowel disease register: Steps towards Crohn's & colitis foundation of Saudi Arabia (CCFSA). Int J Health Sci (Qassim) 2012;6:232-6. [PMID: 23580900 DOI: 10.12816/0006002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
580 Lin H, Dong Y, Fei ZY, Chen XT, Wang RW, Chen QF, Xu Y. Therapeutic effect of salvianolate against ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2013; 21(10): 936-939 [DOI: 10.11569/wcjd.v21.i10.936] [Reference Citation Analysis]
581 Akdoğan RA, Durakoğlugil ME, Kocaman SA, Çiçek Y, Durakoğlugil T, Ergül E, Rakıcı H. Increased pulse wave velocity and carotid intima-media thickness in patients with ulcerative colitis. Dig Dis Sci 2013;58:2293-300. [PMID: 23508984 DOI: 10.1007/s10620-013-2634-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
582 Dolapcioglu C, Guleryuzlu Y, Uygur-Bayramicli O, Ahishali E, Dabak R. Asymptomatic brain lesions on cranial magnetic resonance imaging in inflammatory bowel disease. Gut Liver. 2013;7:169-174. [PMID: 23560152 DOI: 10.5009/gnl.2013.7.2.169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
583 Barnes E, Herfarth H. Clinical features and diagnosis of ulcerative colitis. Advances in the Management of Inflammatory Bowel Disease. Unitec House: Future Medicine Ltd; 2013. pp. 50-66. [DOI: 10.2217/ebo.12.176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
584 Shirazi KM, Somi MH, Rezaeifar P, Fattahi I, Khoshbaten M, Ahmadzadeh M. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol 2012;18:241-7. [PMID: 22824766 DOI: 10.4103/1319-3767.98428] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
585 Chen Z, Zhang H, Xia B, Wang P, Jiang T, Song M, Wu J. Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis. Int J Colorectal Dis 2013;28:1351-8. [PMID: 23456301 DOI: 10.1007/s00384-013-1671-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
586 Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
587 Powar MP, Martin P, Croft AR, Walsh A, Petersen D, Stevenson ARL, Lumley JW, Stitz RW, Radford-smith GL, Clark DA. Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy: Surgical outcomes in acute severe ulcerative colitis. Colorectal Dis 2013;15:374-9. [DOI: 10.1111/j.1463-1318.2012.03188.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
588 Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
589 Maggiori L, Panis Y. Surgical management of IBD--from an open to a laparoscopic approach. Nat Rev Gastroenterol Hepatol. 2013;10:297-306. [PMID: 23419288 DOI: 10.1038/nrgastro.2013.30] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
590 Odes S. Where are we going with ulcerative colitis management? Expert Opin Emerg Drugs 2013;18:1-4. [PMID: 23368663 DOI: 10.1517/14728214.2013.767330] [Reference Citation Analysis]
591 Brito F, Zaltman C, Carvalho AT, Fischer RG, Persson R, Gustafsson A, Figueredo CM. Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis: . European Journal of Gastroenterology & Hepatology 2013;25:239-45. [DOI: 10.1097/meg.0b013e32835a2b70] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
592 Yi F, Zhao J, Luckheeram RV, Lei Y, Wang C, Huang S, Song L, Wang W, Xia B. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013;10:43. [PMID: 23374225 DOI: 10.1186/1743-422x-10-43] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
593 Bakhautdin B, Febbraio M, Goksoy E, de la Motte CA, Gulen MF, Childers EP, Hazen SL, Li X, Fox PL. Protective role of macrophage-derived ceruloplasmin in inflammatory bowel disease. Gut 2013;62:209-19. [PMID: 22345661 DOI: 10.1136/gutjnl-2011-300694] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
594 Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol. 2013;13:20. [PMID: 23351032 DOI: 10.1186/1471-230x-13-20] [Cited by in Crossref: 65] [Cited by in F6Publishing: 73] [Article Influence: 7.2] [Reference Citation Analysis]
595 Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV, Leleiko N, Muise AM, Griffiths AM, Turner D. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013;7:916-922. [PMID: 23339932 DOI: 10.1016/j.crohns.2012.12.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
596 Probert C. Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma. Therap Adv Gastroenterol. 2013;6:33-38. [PMID: 23320048 DOI: 10.1177/1756283x12461395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
597 Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273 [PMID: 23345950 DOI: 10.3748/wjg.v19.i2.265] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
598 Yorulmaz E, Sezgin A, Yorulmaz H, Adali G, Ciftci H. Prolonged QT dispersion in inflammatory bowel disease. World J Gastroenterol 2013; 19(1): 65-71 [PMID: 23326164 DOI: 10.3748/wjg.v19.i1.65] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
599 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
600 Kalafateli M, Triantos C, Theocharis G, Giannakopoulou D, Koutroumpakis E, Chronis A, Sapountzis A, Margaritis V, Thomopoulos K, Nikolopoulou V. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol 2013;26:243-8. [PMID: 24714279] [Reference Citation Analysis]
601 Khanna R, Feagan BG. Through the Looking Glass: A Journey Toward Optimal Endoscopic Assessment of Disease Activity in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2013;11:55-6. [DOI: 10.1016/j.cgh.2012.09.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
602 Sha S, Xu B, Wang X, Zhang Y, Wang H, Kong X, Zhu H, Wu K. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis. 2013;75:245-251. [PMID: 23276768 DOI: 10.1016/j.diagmicrobio.2012.11.022] [Cited by in Crossref: 85] [Cited by in F6Publishing: 95] [Article Influence: 8.5] [Reference Citation Analysis]
603 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
604 Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-136. [PMID: 23121200 DOI: 10.1111/apt.12118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
605 D’haens GR, Rutgeerts PJ. How Should Corticosteroids Be Used in Inflammatory Bowel Disease? Clin Immunother 1996;5:334-40. [DOI: 10.1007/bf03259331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
606 Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-93. [DOI: 10.1007/s00384-012-1602-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
607 Rolny P, Vatn M. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article. Scand J Gastroenterol 2013;48:131-5. [PMID: 23110487 DOI: 10.3109/00365521.2012.733954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
608 Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, Hong SP, Kim TI, Kim WH, Nam CM, Cheon JH. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol 2012; 18(40): 5771-5778 [PMID: 23155319 DOI: 10.3748/wjg.v18.i40.5771] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
609 Matsuoka H, Ikeuchi H, Uchino M, Bando T, Takesue Y, Nishigami T, Tomita N. Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. Int J Colorectal Dis 2013;28:829-34. [PMID: 23080343 DOI: 10.1007/s00384-012-1592-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
610 Uchino M, Ikeuchi H, Matsuoka H, Bando T, Takesue Y, Tomita N. Clinical features and management of pouchitis in Japanese ulcerative colitis patients. Surg Today 2013;43:1049-57. [DOI: 10.1007/s00595-012-0377-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
611 Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol 2012;5:77-83. [PMID: 24833937 DOI: 10.4137/CGast.S8673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
612 Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000544. [PMID: 23076890 DOI: 10.1002/14651858.cd000544.pub3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 54] [Article Influence: 2.3] [Reference Citation Analysis]
613 Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543. [PMID: 23076889 DOI: 10.1002/14651858.cd000543.pub3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 51] [Article Influence: 2.5] [Reference Citation Analysis]
614 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915. [PMID: 23063316 DOI: 10.1016/s0140-6736(12)61084-8] [Cited by in Crossref: 342] [Cited by in F6Publishing: 321] [Article Influence: 34.2] [Reference Citation Analysis]
615 Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion. 2012;86 Suppl 1:16-22. [PMID: 23051722 DOI: 10.1159/000341957] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
616 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 526] [Article Influence: 53.9] [Reference Citation Analysis]
617 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 628] [Article Influence: 65.7] [Reference Citation Analysis]
618 Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
619 Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009;3:271-6. [PMID: 21172286 DOI: 10.1016/j.crohns.2009.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
620 Sidoroff M, Kolho K. Glucocorticoid sensitivity in inflammatory bowel disease. Annals of Medicine 2012;44:578-87. [DOI: 10.3109/07853890.2011.590521] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
621 Hanauer SB. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:954-5. [PMID: 22728318 DOI: 10.1016/j.cgh.2012.06.011] [Reference Citation Analysis]
622 Feagan BG, Macdonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis: . Inflammatory Bowel Diseases 2012;18:1785-94. [DOI: 10.1002/ibd.23024] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
623 Jung SA. Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy? Clin Endosc 2012;45:254-62. [PMID: 22977813 DOI: 10.5946/ce.2012.45.3.254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
624 Chan G, Fefferman DS, Farrell RJ. Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. Gastroenterol Clin North Am 2012;41:271-90. [PMID: 22500517 DOI: 10.1016/j.gtc.2012.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
625 Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218-1226.e1-2. [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 14.8] [Reference Citation Analysis]
626 Bennis M, Tiret E. Chirurgische Behandlung der Colitis ulcerosa. coloproctology 2012;34:273-9. [DOI: 10.1007/s00053-012-0275-7] [Reference Citation Analysis]
627 Islam MS, Grainger SL. Do we know how to use corticosteroids in acute severe ulcerative colitis? Frontline Gastroenterol 2012;3:248-51. [PMID: 28839676 DOI: 10.1136/flgastro-2012-100211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
628 Dayan B, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. World J Gastroenterol 2012; 18(29): 3833-3838 [PMID: 22876035 DOI: 10.3748/wjg.v18.i29.3833] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
629 Torun S, Tunc BD, Suvak B, Yildiz H, Tas A, Sayilir A, Ozderin YO, Beyazit Y, Kayacetin E. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol. 2012;36:491-497. [PMID: 22841412 DOI: 10.1016/j.clinre.2012.06.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 100] [Article Influence: 8.2] [Reference Citation Analysis]
630 Atreya R, Neumann H, Neurath MF. [Rational treatment of ulcerative colitis--local or systemic therapy? Surgery?]. MMW Fortschr Med 2012;154:76-8. [PMID: 22957389 DOI: 10.1007/s15006-012-0934-1] [Reference Citation Analysis]
631 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
632 Gearry RB, Falvey JD. Rescue therapy for steroid refractory acute severe ulcerative colitis: more choice, better outcomes? J Gastroenterol Hepatol 2012;27:417-8. [PMID: 22353345 DOI: 10.1111/j.1440-1746.2012.07063.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
633 Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012;27:487-492. [PMID: 22098019 DOI: 10.1111/j.1440-1746.2011.06958.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
634 Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, Nos P, Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis 2013;7:183-91. [PMID: 22784947 DOI: 10.1016/j.crohns.2012.06.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
635 Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, Nos P, Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis. 2013;7:183-191. [PMID: 22784947 DOI: 10.1016/j.crohns.2010.07.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
636 Cholongitas E, Burroughs AK. Letter: ulcerative colitis in patients transplanted for primary sclerosing cholangitis. Aliment Pharmacol Ther 2012;36:296; author reply 297. [PMID: 22747456 DOI: 10.1111/j.1365-2036.2012.05153.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
637 Baik SH, Kim WH. A comprehensive review of inflammatory bowel disease focusing on surgical management. J Korean Soc Coloproctol 2012;28:121-31. [PMID: 22816055 DOI: 10.3393/jksc.2012.28.3.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
638 Amornyotin S. Abstracts of the 43rd Nordic Gastroenterology Congress. June 12-15, 2012. Reykjavik, Iceland. Scand J Gastroenterol 2012;47 Suppl 1:S14-84. [PMID: 22679915 DOI: 10.3109/00365521.2012.697267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
639 Bradley GM, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 2012;6:125-34. [PMID: 22740771 DOI: 10.2147/BTT.S31833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
640 Suárez J, Romero-Zerbo Y, Márquez L, Rivera P, Iglesias M, Bermúdez-Silva FJ, Andreu M, Rodríguez de Fonseca F. Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS One 2012;7:e37729. [PMID: 22662201 DOI: 10.1371/journal.pone.0037729] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
641 Uchino M, Ikeuchi H, Matsuoka H, Bando T, Takahashi Y, Takesue Y, Matsumoto T, Tomita N. Clinical features and management of parastomal pyoderma gangrenosum in inflammatory bowel disease. Digestion. 2012;85:295-301. [PMID: 22584791 DOI: 10.1159/000336719] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
642 Dainese R, Galliani EA, De Lazzari F, D'Incà R, Mariné-Barjoan E, Vivinus-Nebot MH, Hébuterne X, Sturniolo GC, Piche T. Role of serological markers of activated eosinophils in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2012;24:393-7. [PMID: 22293328 DOI: 10.1097/MEG.0b013e328350f91f] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
643 Bavil AS, Somi MH, Nemati M, Nadergoli BS, Ghabili K, Mirnour R, Ashrafi H. Ultrasonographic evaluation of bowel wall thickness and intramural blood flow in ulcerative colitis. ISRN Gastroenterol 2012;2012:370495. [PMID: 22649739 DOI: 10.5402/2012/370495] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
644 Miheller P, Nagy F, Palatka K, Altorjay I, Horváth G, Lőrinczy K, Újszászy L, Virányi Z, Szepes A, Molnár T, Farkas K, Szepes Z, Nyári T, Wittmann T, Tulassay Z. Some data on inflammatory bowel diseases in Hungary: analytical data on ulcerative colistis. Orvosi Hetilap 2012;153:702-12. [DOI: 10.1556/oh.2012.29361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
645 Armuzzi A, Van Assche G, Reinisch W, de Chambrun GP, Griffiths A, Sladek M, Preiss JC, Lukas M, D'haens G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. Journal of Crohn's and Colitis 2012;6:492-502. [DOI: 10.1016/j.crohns.2011.12.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
646 Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010;23:274-84. [PMID: 22131898 DOI: 10.1055/s-0030-1268254] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
647 Stocchi L. Laparoscopic surgery for ulcerative colitis. Clin Colon Rectal Surg. 2010;23:248-258. [PMID: 22131895 DOI: 10.1055/s-0030-1268251] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
648 Nandivada P, Poylin V, Nagle D. Advances in the surgical management of inflammatory bowel disease. Curr Opin Gastroenterol. 2012;28:47-51. [PMID: 22134218 DOI: 10.1097/mog.0b013e32834d8fcb] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
649 Sidoroff M, Kolho K. Glucocorticoids in pediatric inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2012;47:745-50. [DOI: 10.3109/00365521.2012.679681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
650 Suzuki S, Takai-Igarashi T, Fukuoka Y, Wall DP, Tanaka H, Tonellato PJ. Systems analysis of inflammatory bowel disease based on comprehensive gene information. BMC Med Genet 2012;13:25. [PMID: 22480395 DOI: 10.1186/1471-2350-13-25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
651 Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
652 Kuwahara E, Asakura K, Nishiwaki Y, Inoue N, Watanabe M, Hibi T, Takebayashi T. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 2012;47:961-968. [PMID: 22382632 DOI: 10.1007/s00535-012-0558-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
653 Antonelli E, Baldoni M, Giovenali P, Villanacci V, Essatari M, Bassotti G. Intestinal superinfections in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis 2012;6:154-9. [DOI: 10.1016/j.crohns.2011.07.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
654 Santhanam S, Rajamanickam S, Motamarry A, Ramakrishna BS, Amirtharaj JG, Ramachandran A, Pulimood A, Venkatraman A. Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitis. Inflamm Bowel Dis. 2012;18:2158-2168. [PMID: 22374887 DOI: 10.1002/ibd.22926] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
655 Ananthakrishnan AN, Guzman-Perez R, Gainer V, Cai T, Churchill S, Kohane I, Plenge RM, Murphy S. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:789-795. [PMID: 22360370 DOI: 10.1111/j.1365-2036.2012.05022.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
656 Sack DM, Peppercorn MA. Drug Therapy of Inflammatory Bowel Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1983;3:158-76. [DOI: 10.1002/j.1875-9114.1983.tb03245.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
657 Sachar DB. Management of acute, severe ulcerative colitis: Management of severe ulcerative colitis. Journal of Digestive Diseases 2012;13:65-8. [DOI: 10.1111/j.1751-2980.2011.00560.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
658 Mocciaro F, Renna S, Orlando A, Rizzuto G, Sinagra E, Orlando E, Cottone M. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis. 2012;6:681-686. [PMID: 22398101 DOI: 10.1016/j.crohns.2011.11.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
659 Büning J, Fellermann K. [Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare]. Internist (Berl) 2011;52:833-40. [PMID: 21660632 DOI: 10.1007/s00108-010-2797-9] [Reference Citation Analysis]
660 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
661 Kim J, Kim HJ, Lee CK, Kim H, Shin AR, Kang KH, Kim MK, Park HJ, Chung HH, Hwang EJ. Predictors of Steroid Treatment Failure and Validation of Previous Models for Severe Attacks of Ulcerative Colitis. Intest Res 2012;10:251. [DOI: 10.5217/ir.2012.10.3.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
662 Kudo T, Nagata S, Ohtani K, Fujii T, Wada M, Haruna H, Shoji H, Ohtsuka Y, Shimizu T, Yamashiro Y. Pulse steroids as induction therapy for children with ulcerative colitis: Pulse steroids for ulcerative colitis. Pediatrics International 2011;53:974-9. [DOI: 10.1111/j.1442-200x.2011.03405.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
663 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
664 Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114-1122. [PMID: 21299620 DOI: 10.1111/j.1440-1746.2011.06688.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
665 Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Gómez Senent S, Gomollón F, Calvet X, García-planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Pérez Nyssen O, Gisbert JP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study: Infliximab after ciclosporin failure in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2012;35:275-83. [DOI: 10.1111/j.1365-2036.2011.04934.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
666 Mañosa M, Cabré E, Garcia-planella E, Bernal I, Gordillo J, Esteve M, Zabana Y, Gassull MA, Domènech E. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids: . Inflammatory Bowel Diseases 2011;17:2497-502. [DOI: 10.1002/ibd.21634] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
667 Baumgart DC, Grittner U, Steingräber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients: . Inflammatory Bowel Diseases 2011;17:2512-20. [DOI: 10.1002/ibd.21643] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
668 Chiorean MV. Oral versus intravenous steroids to define refractory ulcerative colitis. Inflamm Bowel Dis 2011;17:2503-4. [PMID: 21287674 DOI: 10.1002/ibd.21632] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
669 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 9.6] [Reference Citation Analysis]
670 Brazilian Study Group of Inflammatory Bowel Diseases. Consensus guidelines for the management of inflammatory bowel disease. Arq Gastroenterol. 2010;47:313-325. [PMID: 21140096 DOI: 10.1590/s0004-28032010000300019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
671 Jiang Y, Xia X, Wang W, Lin L, Xu C, Cai Z, Zheng B, Pei J, Shen S, Xia B. Hyperhomocysteinemia and Related Genetic Polymorphisms Correlate with Ulcerative Colitis in Southeast China. Cell Biochem Biophys 2012;62:203-10. [DOI: 10.1007/s12013-011-9283-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
672 Dogan Y, Soylu A, Eren GA, Poturoglu S, Dolapcioglu C, Sonmez K, Duman H, Sevindir I. Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients. Int J Med Sci 2011;8:540-6. [PMID: 21960745 DOI: 10.7150/ijms.8.540] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
673 Bennis M, Tiret E. Surgical management of ulcerative colitis. Langenbecks Arch Surg. 2012;397:11-17. [PMID: 21922296 DOI: 10.1007/s00423-011-0848-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
674 Akman T, Akarsu M, Akpinar H, Resmi H, Taylan E. Erythrocyte deformability and oxidative stress in inflammatory bowel disease. Dig Dis Sci 2012;57:458-64. [PMID: 21901259 DOI: 10.1007/s10620-011-1882-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
675 Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
676 López-Palacios N, Mendoza JL, Taxonera C, Lana R, López-Jamar JM, Díaz-Rubio M. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med 2011;22:621-5. [PMID: 22075292 DOI: 10.1016/j.ejim.2011.06.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
677 Kato J, Kuriyama M, Hiraoka S, Yamamoto K. Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients? J Gastroenterol Hepatol 2011;26:683-7. [PMID: 21054518 DOI: 10.1111/j.1440-1746.2010.06562.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
678 Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4:129-143. [PMID: 21694814 DOI: 10.1177/1756283x11398930] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
679 Román ALS, Muñoz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol 2011; 17(22): 2723-2733 [PMID: 21734780 DOI: 10.3748/wjg.v17.i22.2723] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
680 Thia KT, Li M, Ling KL, Kong SC, Ooi CJ. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:809-815. [PMID: 20645318 DOI: 10.1002/ibd.21382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
681 Travis SPL, Higgins PDR, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’haens G. Review article: defining remission in ulcerative colitis: Review: remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2011;34:113-24. [DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 10.9] [